

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00012418	James Hotaling	Co-Investigator	IRB_00073305	Preliminary investigation of erectile function using a non-invasive measurement device	The investigator has an equity interest in Andro360, the company whose device will be evaluated in this study.	no			yes	Andro360	Value cannot be readily determined	no	
CRV_00013956	Anne Blaschke	Co-Investigator	IRB_00042895	PARAPNEUMONIC EMPYEMA: USE OF MOLECULAR METHODS TO IDENTIFY PATHOGENS AND OUTCOME	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00036664	Anne Blaschke	Co-Investigator	IRB_00089825	FilmArray Direct: Rapid Diagnosis of Antimicrobial-Resistant Pathogens from Blood	The investigator's licensed intellectual property will be evaluated in the study.	no			no			yes	Value cannot be readily determined
CRV_00040825	Jeremy Giltland	Principal Investigator	IRB_00091705	Fluoroscopic Grid use in Total Hip Arthroplasty	The investigator has an equity interest in OrthoGrid Technologies, whose technology is being evaluated in the study. The investigator also discloses he is a co-inventor of the technology.	no			yes	OrthoGrid Technologies	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00048955	Mark Yandell	Co-Investigator	IRB_00088405	GENETIC EPIDEMIOLOGY OF HEMATOLOGICAL MALIGNANCIES	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00049463	Gabor Marth	Co-Investigator	IRB_00065564	Utah Genome Project	The investigator's intellectual property is being used in the research, and is exclusively licensed to Frameshift Labs (a non-publicly company in which the investigator has significant equity interest).	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00065016	Brook Martin	Principal Investigator	IRB_00099871	Influence of an expanded mandatory bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	The investigator reports significant equity interest in Statix, LLC (formerly known as Gold Standard Research), a non-publicly traded company which was contracted for use of their web-enabled content management system to help collect patient-reported outcomes. Per investigator, secondary analysis of this data will be performed in this study.	no			yes	Statix, LLC	Value cannot be readily determined	no	
CRV_00066629	Kent Bachus	Principal Investigator	IRB_00011755	Biomechanical Testing of Orthopaedic Devices Using Decedent Tissue Models	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00068823	K-T VARLEY	Co-Investigator	IRB_00041211	Cancer Genetics Study	The investigator's licensed intellectual property will be used in the study. The investigator has significant financial interest in the licensing company.	yes	Kailos Genetics	\$20,000-39,999	yes	Kailos Genetics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069229	Mark Yandell	Co-Investigator	IRB_00066143	Biological Determinants of Brain Variation in Autism	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069233	Mark Yandell	Co-Investigator	IRB_00021080	Pediatric Cardiology Genotype-Phenotype Core	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069235	Mark Yandell	Co-Investigator	IRB_00006042	Genetics Of Autism	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069236	Mark Yandell	Co-Investigator	IRB_00065564	Utah Genome Project	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00069474	Jeremy Giltland	Co-Investigator	IRB_00075446	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	The investigator has a significant financial interest in Smith & Nephew, whose products may be analyzed in this study.	yes	Smith & Nephew	\$5,000-9,999	no			no	
CRV_00070987	Dennis Parker	Co-Investigator	10045663	Validation and translation of a non-invasive, MR-guided breast cancer therapy	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00070993	Allison Payne	Principal Investigator	10045663	Validation and translation of a non-invasive, MR-guided breast cancer therapy	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00071050	Mark Yandell	Co-Investigator	IRB_00096990	GENETIC EPIDEMIOLOGY OF BREAST CANCER	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00071131	Doug Christensen	Co-Investigator	10045663	Validation and translation of a non-invasive, MR-guided breast cancer therapy	The investigator's licensed intellectual property will be used in the research.	no			no			yes	Value cannot be readily determined
CRV_00073806	Jeremiah Alt	Co-Investigator	10049369	A NOVEL GLYCOSAMINOGLYCAN-BASED THERAPEUTIC FOR CHRONIC RHINOSINUSITIS	The investigator has a significant financial interest in the study sponsor Glycomira, a non-publicly traded company.	no			yes	Glycomira Therapeutics	Value cannot be readily determined	no	
CRV_00074000	Jeremiah Alt	Principal Investigator	IRB_00074325	Sinonasal Tissue Repository	The investigator has a significant financial interest in Glycomira Therapeutics, a non-publicly traded company which will utilize specimens from this tissue bank for research.	no			yes	Glycomira Therapeutics	Value cannot be readily determined	no	
CRV_00074585	Karen Eilbeck	Co-Investigator	IRB_00013791	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00074587	Mark Yandell	Principal Investigator	IRB_00013791	Utah Infertility Registry- Polycystic Ovary Syndrome (UIR-PCOS)	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	\$80,001 to \$99,999	yes	IDbyDNA; Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00074592	Mark Yandell	Principal Investigator	IRB_00100891	ENDOMETRIOSIS IMPRINTS (infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms (IIMP	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00074906	Mark Yandell	Principal Investigator	IRB_00021614	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00074911	Mark Yandell	Co-Investigator	IRB_00017613	Familial kinship analysis in patients with Mullerian anomalies	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00075563	Philip Bernard	Co-Investigator	IRB_00096990	GENETIC EPIDEMIOLOGY OF BREAST CANCER	The investigator's licensed intellectual property will be used in the study. The investigator has a significant financial interest in Bioclassifier, which holds the license to the intellectual property.	no			yes	Bioclassifier, LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00075628	Michael YU	Principal Investigator	10045626	TARGETING COLLAGEN MECHANICAL DAMAGE USING COLLAGEN HYBRIDIZING PEPTIDES	The investigator's licensed intellectual property will be used in the study. The investigator has a significant financial interest with 3Helix, a company that is commercializing the collagen hybridizing peptide used in this project.	no			yes	3Helix	Value cannot be readily determined	yes	
CRV_00077276	Karen Eilbeck	Data Analyst	IRB_00024408	Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collection Study	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA	\$60,001 to \$79,999	yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00077278	Mark Yandell	Principal Investigator	IRB_00024408	Utah Markers of Risk: Endometriosis (MORENDO) A Longitudinal Sample Collection Study	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	IDbyDNA	\$60,001 to \$79,999	yes	IDbyDNA	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00078926	Dennis Parker	Co-Investigator	IRB_00114506	Validation of a Protocol for a Non-Invasive, Magnetic Resonance Guided Breast Cancer Therapy	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00082050	Christopher Peters	Co-Investigator	IRB_00116363	A Prospective Multicenter Longitudinal Cohort Study of the mymobility Platform	The investigator's intellectual property will be used in the study. The intellectual property is licensed to Zimmer Biomet, the study sponsor. The investigator receives remuneration Zimmer Biomet for consulting services.	yes	Zimmer Biomet	\$20,001 to 39,999	no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00085416	Glenn Prestwich	Co-Investigator	10049346	LOCALIZED DELIVERY OF GLYCOSAMINOCLYCAN ETHERS FOR THE TREATMENT OF RADIATION-INDUCED PROCTITIS	The investigator reports a significant equity interest with Glycomira Therapeutics, whose technology will be used in the project. The investigator is also an inventor of the technology licensed to Glycomira.	no			yes	Glycomira Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00086263	Mark Yandell	Co-Investigator	IRB_00067518	Retrospective study of prognostic and predictive factors in advanced urologic cancers	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00086963	Florian Soltzbacher	Principal Investigator	10047537	DEVELOPMENT AND TRANSLATION OF AN INTRACRANIAL AUDITORY NERVE IMPLANT	The investigator reports a significant financial interest in Blackrock Microsystems, who will be providing equipment for this project. The investigator's intellectual property licensed to Blackrock Microsystems will be used in the project.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00089246	Joshua Schiffman	Principal Investigator	10051735	ACCELERATING EP53 NANOPARTICLES FOR CANCER THERAPY	The investigator reports a significant financial interest in PEEL Therapeutics, the sponsor of the study. The investigators intellectual property will be used in this project.	yes	PEEL Therapeutics	\$60,000 to \$79,999	yes	PEEL Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00095904	Mark Yandell	Co-Investigator	IRB_00095807	A Pilot Study of Discovery-Driven Big Data Science: Empowering Evidence-Based Research to Improve the Value of Pediatric Cardiovascular Care	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	ID byDNA; Fabric Genomics	\$80,001 to \$99,999	yes	ID byDNA; Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00097703	Mark Yandell	Co-Investigator	IRB_00096551	The Familiality of Diabetes and Diabetes-Related Complications	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00098515	Marvin Moore	Key Personnel	IRB_00119139	Utah/Primary's Center for Pediatric Personalized Medicine (UP-cPPM)	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00099149	Florian Soltzbacher	Principal Investigator	10052265	DEVELOPMENT AND TRANSLATION OF SIC BASED ENCAPSULATION FOR CHRONIC NEURAL IMPLANTS IN A NOVEL AUDITORY NERVE IMPLANT	The investigator reports significant financial interests in Blackrock Microsystems, the sponsor of the project. The investigator's intellectual property will be involved in this project. The intellectual property is licensed to Blackrock Microsystems.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00100565	Karen Eitbeck	Data Analyst	IRB_00100891	ENDOMETRIOSIS IMPRINTS (Infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms (IMP	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Omnicia	\$20,000 to \$39,999	yes	Omnicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00100732	Marvin Moore	Key Personnel	IRB_00125940	Personalized Pediatric Medicine (PPM) at the University of Utah	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00100739	JASON SHEPHERD	Principal Investigator	10051280	VIRUS-LIKE INTERCELLULAR COMMUNICATION IN THE NERVOUS SYSTEM	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	no			yes	VNV Newcom	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00101451	ALANA WELM	Principal Investigator	10054932	PDX TRIAL CENTER FOR BREAST CANCER	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00101453	Bryan Welm	Co-Investigator	10054932	PDX TRIAL CENTER FOR BREAST CANCER	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00101754	Mark Yandell	Co-Investigator	10051171	PRIMARY OVARIAN INSUFFICIENCY: ETIOLOGY AND COMORBID DISEASE	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Omicia Inc (Fabric Genomics)	\$80,000 to \$99,999	yes	Omicia Inc (Fabric Genomics)	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00102072	Marvin Moore	Key Personnel	IRB_00126184	Genetic analysis of undiagnosed conditions	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00102073	Mark Yandell	Co-Investigator	IRB_00126184	Genetic analysis of undiagnosed conditions	The investigator's intellectual property will be used in this project. The investigator reports a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00105378	James Hotaling	Co-Investigator	10053353	STREAM DX: POINT OF CARE CELLULAR ENABLED IOT COMMUNICATION HUB FOR IMPROVED DIAGNOSIS, MONITORING, AND POST-TREATMENT EVALUATION OF LUTS	The investigator's intellectual property is being evaluated in the study. The intellectual property has been exclusively licensed to StreamDX, a non-publicly traded company in which the investigator has significant equity interest.	no			yes	StreamDx	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00108069	Mark Yandell	Co-Investigator	IRB_00086989	A community driven framework for genome based clinical diagnostics.	The investigator's licensed intellectual property will be used in the research. The investigator has a significant financial interest in the licensing company.	yes	Fabric Genomics	\$80,001 to \$99,999	yes	Fabric Genomics formerly known as Omicia	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00108830	James Hotaling	Co-Investigator	10055192	SPERM SAMPLE PREPARATION FOR POINT OF CARE APPLICATIONS	The investigator has a significant financial interest in NanoNC, the sponsor of the project. The investigator's intellectual property will be used in this project. This intellectual property is licensed by NanoNC.	no			yes	NanoNC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00108865	Binglian Feng	Co-Investigator	IRB_00062148	Head and neck cancer susceptibility genes	The investigator's intellectual property will be used in this project. The intellectual property is licensed to Ambry Genetics Corporation.	no			no			yes	Value cannot be readily determined
CRV_00109550	Anne Blaschke	Co-Investigator	10048481	ONGOING EVALUATION OF THE IMPACT OF THE INTRODUCTION OF PNEUMOCOCCAL CONJUGATE VACCINE (PCV-13) ON THE INCIDENCE OF PARAPNEUMONIC EMPYEMA AND OTHER INVASIVE PNEUMOCOCCAL DISEASE IN CHILDREN AND ADOLESCENTS IN ORANGE COUNTY, CALIFORNIA	The investigator reports a significant financial interest in BioFire Diagnostics, LLC. The investigator reports that her intellectual property will be used in this project.	yes	Biofire	\$5,000 to \$9,999	no			yes	Value cannot be readily determined
CRV_00109909	Kyle Turner	Principal Investigator	IRB_00129444	Relational Leadership Initiative: Assessing Implementation and Learning Outcomes of an Interprofessional, Cross-Generational Collaborative	The investigator reports a significant financial interest from Primary Care Progress, who provides program management services for the project.	yes	Primary Care Progress	\$10,000 to \$19,999	no			no	
CRV_00110507	AUSTAIR WARD	Data Analyst	IRB_00115011	University of Utah - Intermountain West Clinical Site for the Undiagnosed Disease Network (UDN)	The investigator has a significant financial interest in Frameshift Labs Inc., whose tool will be used in this project. The investigator's licensed intellectual property will be involved in the project. The intellectual property is licensed to Frameshift Labs.	yes	Frameshift Labs	Over \$100,000	yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00111987	Mark Yandell	Principal Investigator	IRB_00125940	The Utah NeoSeq Project	The investigator has a significant financial interest in Fabric Genomics, a company that creates tools that will be used in the analysis. The investigator's licensed intellectual property will be used in the project.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomic	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00112451	Christopher Gregg	Co-Investigator	IRB_00130951	Behavioral Stories for Health	The investigator has a significant financial interest in Storyline Health, a company that manufactures a smartphone app that will be used in this study.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00113309	Andrew Garrison	Co-Investigator	IRB_00130792	An educational intervention to address barriers to treating opioid use disorder at Community Health Centers, Inc., in Salt Lake City, UT.	The investigator has a significant financial interest in Community Health Centers, Inc., a company that will be involved in the study.	yes	Community Health Centers, Inc	Over \$100,000	no			no	
CRV_00114287	Christian Yost	Principal Investigator	IRB_00131977	NETosis in Human Respiratory Infection	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00114451	Marvin Moore	Key Personnel	IRB_00108137	Rapid Sequencing in Acutely Ill Infants in the NICU	The investigator has a significant financial interest in Fabric Genomics, whose software will be involved in this project. The investigator's licensed intellectual property will be involved in the project. This intellectual property is licensed to Fabric Genomics.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00115340	Christopher Peters	Co-Investigator	10032753	A Clinical Evaluation of the Vanguard XP Bicruciate Knee System Early Intraoperative & Candidacy Assessment	The investigator's licensed intellectual property will be evaluated in the research.	no			no			yes	Value cannot be readily determined
CRV_00115360	Christopher Peters	Co-Investigator	IRB_00075446	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	The investigator's licensed intellectual property will be evaluated in the research.	no			no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00115368	Christopher Peters	Co-Investigator	IRB_00062862	Vanguard SSK 360 Revision Knee System Global Data Collection	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00116290	Christian Yost	Principal Investigator	IRB_00011919	NETs: Protection or Harm in Neonatal Inflammation or Infection	The investigator's licensed intellectual property will be involved in the project.	no			no			yes	Value cannot be readily determined
CRV_00117562	Mark Yandell	Co-Investigator	10053650	A NOVEL ROLE FOR NFATC1 IN MODULATING CARDIAC EXCITABILITY	The investigator's licensed intellectual property will be used in the project. The intellectual property is licensed to Fabric Genomics, a company in which the investigator has a significant financial interest.	no			no			yes	Value cannot be readily determined
CRV_00118159	Christopher Gregg	Co-Investigator	IRB_00131657	COVID-19 & the Effect of Social Isolation on Health	The investigator has a significant financial relationship with Storyline Health, a company that will be involved in the research.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00118187	Alexander Henrie	Data Analyst	IRB_00017613	Familial kinship analysis in patients with Mullerian anomalies	The investigator has a significant financial interest in Backdrop Health Inc. Backdrop developed software that will be used in this study.	no			yes	Backdrop Health Inc	Value cannot be readily determined	no	
CRV_00118625	Kensaku Kawamoto	Principal Investigator	IRB_00134238	Design, Implementation and Evaluation of Scalable Decision Support for Diabetes Care	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00212119	Florian Solzbacher	Principal Investigator	10055936	DEVELOPMENT OF A HIGH (60) CHANNEL NEUROSTIMULATOR FOR AN AUDITORY NERVE IMPLANT	The investigator has significant financial interests (remuneration and equity) in Blackrock Microsystems, the sponsor of the project. The investigator's licensed intellectual properties will be directly involved in the project. These intellectual properties are licensed to Blackrock Microsystems.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_002121857	Gabor Marth	Principal Investigator	10055226	CARDIOVASCULAR DEVELOPMENTAL BIOLOGY DATA RESOURCE CENTER (CDDRC)	The investigator has a significant financial interest in Frameshift Labs, LLC, who will be involved in the project. The investigator's licensed intellectual property will be used in the project.	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00213008	Kerry Kelly	Principal Investigator	10054853	SCC-IRG TRACK 2: SMART AIR: INFORMING DRIVING BEHAVIOR THROUGH DYNAMIC AIR-QUALITY SENSING AND SMART MESSAGING	The investigator reports that the technology developed from this project may be commercialized by Tetrad: Sensor Network Solutions, LLC.	no			yes	Tetrad: Sensor Network Solutions, LLC	Value cannot be readily determined	no	
CRV_00213124	Alexander Henrie	Data Analyst	IRB_00100891	ENDOMETRIOSIS IMPRINTS (Infertility, Mortality (cancers), Pain, Reproductive outcomes (time to pregnancy, prematurity, preeclampsia, etc), Inheritance patterns (Is endometriosis one or multiple entities?), Noisome Traits (comorbidities) and Symptoms (IMP	The investigator has a significant financial interest in Backdrop Health Inc, who are in the process of commercializing the software that will be used in this project.	no			yes	Backdrop Health Inc	Value cannot be readily determined	no	
CRV_002125946	Jill Shea	Co-Investigator	10056694	A NOVEL BIODEGRADABLE NERVE CONDUIT DRUG DELIVERY DEVICE FOR PERIPHERAL NERVE REPAIR	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_002128069	Kyle Turner	Principal Investigator	IRB_00134146	Healthcare workforce experiences with relational leadership programming through the lens of self-determination theory	The investigator has a significant financial interest in Primary Care Progress, a company that will be involved in the project.	yes	Primary Care Progress	\$5,000 to \$9,999	no			no	
CRV_002128789	Burt Richards	Co-Investigator	IRB_00010201	Genetic and Molecular Studies Of Eye Diseases	The investigator reports a significant financial interest (licensed intellectual property) that will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_002129601	Mark Yandell	Principal Investigator	10055224	BRIDGING THE GAP BETWEEN GENOMICS AND CLINICAL OUTCOMES IN CHD	The investigator's licensed intellectual properties will be involved in this project. These technologies are licensed to Backdrop Health, IDbyDNA, and Fabric Genomics. The investigator has a significant financial interest in Fabric Genomics, IDbyDNA, and Backdrop Health.	yes	IDbyDNA Inc Fabric Genomics	\$60,001 to \$79,999; \$80,000 to \$99,999	yes	Fabric Genomics; IDbyDNA Inc; Backdrop Health	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00131368	Josh Bonkowsky	Principal Investigator	10058507	SYSTEMS FOR RAPID GENERATION OF ZEBRAFISH MUTANTS AND ZEBRAFISH EMBRYO HANDLING	The investigator has intellectual property that will be used in this research. The technology is licensed to wFluidx, a company in which the investigator has a significant financial interest.	no			yes	wFluidx	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00132830	Christian Yost	Co-Investigator	IRB_00139857	Regulation of neutrophil extracellular traps and NET-inhibitory factors in ARDS	The investigator's licensed intellectual property will be used in the study. The intellectual property is licensed to Peel Therapeutics, Inc.	no			no			yes	Value cannot be readily determined
CRV_00134746	Alexander Becraft	Principal Investigator	IRB_00140200	Mental Health Prevention and Promotion: Leveraging positive psychological interventions and social entrepreneurship to build resilience and well-being in college students	The investigator has a significant financial interest in Wellbeing Elevated, Inc. Wellbeing Elevated's intellectual property will be evaluated in the study.	yes	Wellbeing Elevated, Inc.	\$10,000 to \$19,999	yes	Wellbeing Elevated, Inc.	Value cannot be readily determined	no	
CRV_00134917	Gordon Lemmon	Data Analyst	IRB_00136167	EXEMPTION UMBRELLA: Assembling de-identified machine learning datasets for outcomes research.	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134918	Gordon Lemmon	Data Analyst	IRB_00021614	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134920	Gordon Lemmon	Data Analyst	IRB_00067518	Retrospective study of prognostic and predictive factors in advanced urologic cancers	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134922	Gordon Lemmon	Data Analyst	IRB_00095807	APilot Study of Discovery-Driven Big Data Science: Empowering Evidence-Based Research to Improve the Value of Pediatric Cardiovascular Care	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134923	Gordon Lemmon	Data Analyst	IRB_00017613	Familial kinship analysis in patients with Mullerian anomalies	The investigator reports a significant financial interest (equity) in Backdrop Health, a non-publicly traded company. Technology owned by Backdrop will be used in this project.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00134924	Gordon Lemmon	Data Analyst	IRB_00006042	Genetics Of Autism	The investigator has a significant financial interest (equity) in Backdrop Health Inc.	no			yes	Backdrop Health	Value cannot be readily determined	no	
CRV_00135422	Jeremy Gilliland	Co-Investigator	10057465	TRIDENT II ACETABULAR SHELL REVISION STUDY	The investigator reports a significant financial interest (remuneration) from Styker, the sponsor of the project.	yes	Stryker	\$10,000 to \$19,999	no			no	
CRV_00136439	Christopher Gregg	Key Personnel	IRB_00135711	Behavioral micro-features in treatment-resistant mood disorders	The investigator reports a significant financial interest (equity) in Storyline Health.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00140138	JAN PIERCE	Co-Investigator	IRB_00103515	A RANDOMIZED, DOUBLE-BLUNDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140160	John Phillips	Principal Investigator	IRB_00103515	A RANDOMIZED, DOUBLE-BLUNDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140409	Eric Garland	Principal Investigator	10061010	FROELIGER NICOTINE R01 SUB: NEURAL MECHANISMS MEDIATING APPETITIVE REGULATION AND SMOKING IN NICOTINE ADDICTION	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00140418	Eric Garland	Principal Investigator	10050111	MUSC R01 NEURAL MECHANISMS MEDIATING APPETITIVE REGULATION AND SMOKING IN NICOTINE ADDICTION SUBAWARD	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140419	Eric Garland	Principal Investigator	10040208	Targeting Hedonic Dysregulation in Chronic Pain and Opioid Misuse with Mindfulness-Oriented Recovery Enhancement: ARCT in Primary Care	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140420	Eric Garland	Principal Investigator	10040437	Targeting Chronic Pain and Co-Occurring Disorders in the Community with Mindfulness-Oriented Recovery Enhancement	The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest (remuneration) from BehaVR, who has licensed the intellectual property.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140426	Eric Garland	Co-Investigator	10045550	SMART Stepped Care Management for Low Back Pain in Military Health System	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140444	Eric Garland	Principal Investigator	IRB_00129302	Near-infrared spectroscopy-based neurofeedback as adjunct to Mindfulness-Oriented Recovery Enhancement in persons with chronic pain.	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140448	Eric Garland	Co-Investigator	IRB_00116150	SMART LBP: Optimized Multidisciplinary Treatment Programs for Nonspecific Chronic Low Back Pain	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00140817	JAN PIERCE	Co-Investigator	IRB_001128491	A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140818	John Phillips	Co-Investigator	IRB_001128491	A Phase I/II Randomized Double-Blinded Standard of Care (Corticosteroid) vs. Sterile Amniotic Fluid for Osteoarthritis	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	Zero to \$4,999	yes	Eliksa	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00140825	JAN PIERCE	Co-Investigator	IRB_00131761	A Phase I/II Double-Blinded Randomized Prospective Study of Sterile Amniotic Fluid Filtrate Epidural Injection for the treatment of Lumbosacral Radicular Pain due to Spinal Stenosis: The SAFE Trial (Improving Safety and Outcomes in the Treatment of Pain	The investigator's intellectual property is being used in the study. Commercialization is imminent to Eliksa, a non-publicly traded company in which the investigator will hold a significant financial interest.	yes	Eliksa	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00141458	Eric Garland	Co-Investigator	IRB_00141097	Enriched Pain Management for Lumbar Spine Surgery	The investigator reports significant financial interest from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00143734	Mark Yandell	Co-Investigator	10057983	GENETIC AND FUNCTIONAL ANALYSIS OF RAPID RENAL DECLINE IN DIABETES: A FAMILY-BASED APPROACH TO ACCELERATE GENE DISCOVERY	The investigator reports significant financial interest from Backdrop Health Inc. and Fabric Genomics. The investigator's intellectual property licensed to Backdrop Health Inc. and Fabric Genomics (both non-publicly traded) will be used in the study.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics; Backdrop Health Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00145246	Kerry Kelly	Co-Investigator	10060076	A MULTICITY STUDY OF WINTERTIME INVERSIONS AND ACUTE CARDIORESPIRATORY HEALTH EVENTS IN THE WESTERN U.S.	The investigator reports significant financial interest (equity) in Tetrad: Sensor Network Solutions, LLC (a non-publicly traded company). The study will be collecting publicly available data from the Tetrad website.	no			yes	Tetrad: Sensor Network Solutions, LLC	Value cannot be readily determined	no	
CRV_00145593	Jeremy Giltland	Co-Investigator	IRB_00143682	Long term follow-up of Trident II Acetabular Shell	The investigator reports significant remuneration in Stryker, the manufacturer of Trident II acetabular component being used in the study.	yes	Stryker	\$10,000 to \$19,999	no			no	
CRV_00146311	Eric Garland	Principal Investigator	IRB_00091781	Behavioral interventions for active duty service members and veterans with chronic pain conditions and opioid related problems	The investigator reports significant financial interest (remuneration and licensed intellectual property) from BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property being used in the study.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00146928	Andrew Zayachkivsky	Co-Investigator	10058182	NIH/MGH R33: ANTICONVULSANT SCREENING USING CHRONIC EPILEPSY MODELS	The investigator's intellectual property is used in this project. This technology is licensed to BIOPAC, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BIOPAC	\$5,000 to \$9,999	no			yes	Value cannot be readily determined
CRV_00148355	Eric Garland	Co-Investigator	10058817	BEHAVR R43/R44 SUBAWARD	The investigator's intellectual property will be used in the study. This technology is licensed to BehaVR, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00148382	Eric Garland	Principal Investigator	IRB_00130630	Mindfulness Oriented Recovery Enhancement (MORE) with Ketamine Assisted Psychotherapy (KAP) for the Treatment of Opioid Use Disorder	The investigator's intellectual property will be used in the study. This technology is licensed to BehaVR, a non-publicly traded company in which the investigator has a significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00149211	David Warren	Key Personnel	10061070	INTELLIGENT NEURAL INTERFACES EXPERIMENTAL FOLLOW-ON	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00149288	BENJAMIN SANCHEZ TERRONES	Co-Investigator	IRB_00145489	Development and Human Testing of an Impedance-Electromyography System for the Diagnosis of Muscular Disorders. HAYSTACK	The investigator reports significant financial interest (equity interest) and licensed intellectual property in Haystack Diagnostics, Inc. a non-publicly traded company, the sponsor of the study.	no			yes	Haystack Diagnostics, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00149821	Florian Solzbacher	Co-Investigator	10059510	ENGINEERING A TRANSITION MICRO- ELECTRODE ARRAY FOR LARGE-SCALE BRAIN RECORDING AND MODULATION	The investigator reports significant financial interest (remuneration and equity) in Blackrock Microsystems Europe GmbH and Blackrock Microsystems. The company is commercializing neural interface electrodes and licensing technologies from the University.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	no	
CRV_00149998	Bruce Gale	Principal Investigator	10058507	SYSTEMS FOR RAPID GENERATION OF ZEBRAFISH MUTANTS AND ZEBRAFISH EMBRYO HANDLING	The investigator reports a significant financial interest with wFluidx, who has licensed the investigator's intellectual property being used in the study, and a significant financial interest with the study sponsor Advanced Conceptions (formerly NanoNC).	yes	Advanced Conceptions	\$5,000 to \$9,999	yes	Advanced Conceptions	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00150162	Christopher Gregg	Co-Investigator	IRB_00143135	Precision Behavioral Oncology - Deep AI Behavioral Profiling to Reveal Mental and Behavioral Phenotypes Shaping Cancer Outcomes	The investigator reports significant financial interest in Storyline Health, which provides the artificial intelligence platform being used in the study to build models of cancer patient care.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00150227	Kent Lai	Principal Investigator	10055108	MRNA THERAPY FOR CLASSIC GALACTOSEMIA	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00150455	Derek Dosdall	Principal Investigator	10059746	ANTITACHYCARDIA PACING AND IMPROVED LEAD FOR VENTRICULAR CONDUCTION SYSTEM STIMULATION	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00150218	Julia Batten	Co-Investigator	IRB_00130937	Seagen SGN22E-003 >> An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer	The investigator reports significant financial interest with Seagen, who sponsors the study and manufactures enfortumab vedotin.	yes	Seagen (Seattle Genetics Inc.)	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00152245	Florian Solzbacher	Principal Investigator	10063055	DEVELOPMENT OF A HIGH (60) CHANNEL NEUROSTIMULATOR FOR AN AUDITORY NERVE IMPLANT	The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest in Blackrock Microsystems, the study sponsor.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00155905	Christian Yost	Principal Investigator	10048161	NETS: PROTECTION OR HARM IN NEONATAL INFLAMMATION AND INFECTION	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00157132	K-T VARLEY	Principal Investigator	10047239	LONGITUDINAL MODELS OF BREAST CANCER FOR STUDYING MECHANISMS OF THERAPY RESPONSE AND RESISTANCE	The investigator reports significant financial interest with Kallos Genetics Inc., a non-publicly traded company which is helping to evaluate technology being studied. The investigator's licensed intellectual property will be used in the project.	yes	Kallos Genetics	\$20,000 to \$39,999	yes	Kallos Genetics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00157197	Kensaku Kawamoto	Principal Investigator	10060557	CLINICAL DECISION SUPPORT SYSTEM (CDSS) TO OPTIMIZE DISEASE MANAGEMENT	The investigator's intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00161151	JAN PIERCE	Key Personnel	IRB_00067855	Platelet Lysate Derived Material for use as a Fetal Serum Substitute	The investigator's licensed intellectual property will be used in the study. The investigator has a significant financial interest with the licensing company, Eliksa.	yes	Eliksa	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00161666	Ross Whitaker	Co-Investigator	10060076	A MULTICITY STUDY OF WINTERTIME INVERSIONS AND ACUTE CARDIORESPIRATORY HEALTH EVENTS IN THE WESTERN U.S.	The investigator reports a significant financial interest in Tetrad: Sensor Network Solutions, LLC (a non-publicly traded company). They will be collecting publicly available data from the Tetrad website.	no			yes	Tetrad: Sensor Network Solutions, LLC	Value cannot be readily determined	no	
CRV_00162661	James Patten	Key Personnel	10060158	TRANSFORMING UINTA BASIN EARTH MATERIALS FOR ADVANCED PRODUCTS (TUBE-MAP)	The investigator reports a significant financial interest in Red Leaf Resources, a company that holds leases in the Uintah Basin and that could potentially benefit from the results of this project. James Patten's work on this project is independent of Red Leaf Resources and is being conducted as a private consultant.	yes	Red Leaf Resources	Over \$100,000	yes	Red Leaf Resources	Value cannot be readily determined	no	
CRV_00163151	Kevin Brennan	Co-Investigator	IRB_00068751	Memantine for Enhanced Stroke Recovery	The investigator reports significant financial interest from Abbvie, the manufacturer of the study drug.	yes	Abbvie Inc	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00164037	Mary Scholand	Principal Investigator	10040360	Bronchial Sample Collection for a Novel Genomic Test.	The investigator reports significant financial interest from the study sponsor Veracyte.	yes	Veracyte	\$5,000 to \$9,999	no			no	
CRV_00164591	Jeremy Gilliland	Co-Investigator	IRB_00145076	Mid-term Survival of the Insignia Stem in Primary Total Hip Arthroplasty	The investigator reports significant financial interest in the study sponsor Stryker.	yes	Stryker	\$10,000 to \$19,999	no			no	
CRV_00164960	ALUSTAIR WARD	Co-Investigator	IRB_00150395	A web software system supporting team-based, longitudinal genomic diagnostic care	The investigator reports significant financial interest in Frameshift Labs, LLC a non-publicly traded company that will be involved with the study. The investigator's licensed intellectual property will be used in the study.	yes	Frameshift Labs	Over \$100,000	yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00165759	Florian Solzbacher	Principal Investigator	10060302	A WIRELESS MICRO-ECOG PROSTHESIS FOR SPEECH	The investigator reports significant financial interest in Blackrock Microsystems Europe GmbH and Blackrock Microsystems, who is involved in the study.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	no	
CRV_00167445	Mitchell Wulfman	Key Personnel	IRB_00140200	Mental Health Prevention and Promotion: Leveraging positive psychological interventions and social entrepreneurship to build resilience and well-being in college students	The investigator reports significant financial interest in the company Wellbeing Elevated, Inc. Well-Being is delivering the mental health programming in group sessions.	yes	Wellbeing Elevated, Inc.	Over \$100,000	yes	Wellbeing Elevated, Inc.	Value cannot be readily determined	no	
CRV_00168757	Jill Shea	Principal Investigator	10063463	NOVEL SUSTAINED RELEASE LOCAL ANESTHETIC WOUND DRESSING FOR SUPERFICIAL AND PARTIAL-THICKNESS DERMAL INJURIES	This investigator reports significant financial interest in the study sponsor, Rebel Medicine, a non-publicly traded company.	no			yes	Rebel Medicine	Value cannot be readily determined	no	
CRV_00168888	Gabor Marth	Principal Investigator	10061038	CALYPSO: A WEB SOFTWARE SYSTEM SUPPORTING TEAM-BASED, LONGITUDINAL GENOMIC DIAGNOSTIC CARE	The investigator reports significant financial interest in Frameshift Labs, LLC which will be involved in this project. The investigator's licensed intellectual property will be used in this project.	no			yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00169045	Karen Ellbeck	Data Analyst	IRB_00021614	Endometriosis: Natural History, Diagnosis, and Outcomes (ENDO)	The investigator's intellectual property is being used in the research. The investigator has a significant financial interest in Fabric Genomics, the licensor of the technology.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00169733	Allison Payne	Co-Investigator	IRB_00148669	Breast MRgFUS: A Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00169820	Christian Yost	Co-Investigator	10060581	HUMAN PLATELET PAR4: NOVEL ACTIVATION, INTERINDIVIDUAL VARIATION, AND NEUTROPHIL INTERACTIONS IN VIVO AND IN VITRO	This investigator's intellectual property is being used in the project.	no			no			yes	Value cannot be readily determined
CRV_00170952	Benjamin Steinberg	Principal Investigator	10061417	SOTALOL REGISTRY STUDY	Investigator reports a significant financial interest in AltaThera, the study sponsor.	yes	AltaThera	\$5,000 to \$9,999	no			no	
CRV_00171355	Gordon Lemmon	Data Analyst	IRB_00103256	Role of Genetic and Epigenetic Factors in Cardiac Failure and Recovery	The investigator's intellectual property will be used in the study. The investigator has a significant financial interest in Backdrop Health, the licensor of the technology.	no			no			yes	Value cannot be readily determined
CRV_00171450	Marshall Smith	Principal Investigator	10050849	PHASE I - A TRIAL TO DEVELOP SURGICAL TECHNIQUES BASED ON AMNIOTIC TISSUE IN ANIMALS AND PHASE II - A TRIAL TO TRANSLATE NEW SURGICAL TECHNIQUES TO HUMAN PATIENTS) OF RESEARCH INTO IDIOPATHIC STENOSIS	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00171588	Gregory Clark	Co-Investigator	10063790	OPTIMAL FEATURE GENERATION FOR PERIPHERAL NERVE INTERFACES TO GUIDE THE DEVELOPMENT OF DEXTEROUS NEUROPROSTHESES	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172483	Jessica Walsh	Principal Investigator	IRB_00117215	Accelerating psoriatic arthritis detection in patients with psoriasis: direct-to-patient administration of screening questionnaires (D2P Screening)	The investigator reports a significant financial interest with the study sponsor Global Healthy Living Foundation.	yes	Global Healthy Living Foundation	\$5,000 to \$9,999	no			no	
CRV_00172515	Phillip Warner	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172516	Salvador Rodriguez	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172525	Scott Summers	Principal Investigator	10062553	THE ROLE OF CERAMIDES IN THE PANCREATIC BETA CELL	The investigator has a significant financial interest in Centaurus Therapeutics, which provides the compounds used in the study.	yes	Centaurus Therapeutics	\$10,000 to \$19,999	yes	Centaurus Therapeutics	Value cannot be readily determined	no	
CRV_00172830	Russell Butterfield	Principal Investigator	IRB_00131062	EMBARC: A Phase 3 Multinational, Randomized, Double-Blind, Placebo-Controlled Systemic Gene Delivery Study to Evaluate the Safety and Efficacy of SRP-9001 in Subjects With Duchenne Muscular Dystrophy (EMBARC)	The investigator reports a significant financial interest in the study sponsor Sarepta Therapeutics.	yes	Sarepta Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00172847	Russell Butterfield	Principal Investigator	10056662	A MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SYSTEMIC GENE DELIVERY STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF SRP-9001 IN SUBJECTS WITH DUCHENNE MUSCULAR DYSTROPHY WHO ARE AGED 4-7 YEARS	The investigator reports significant financial interest in Sarepta Therapeutics, the sponsor of the project.	yes	Sarepta Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00172928	Claude Nanjo	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00172934	Peter Chalmers	Principal Investigator	10061174	OUTCOMES OF SHOULDER ARTHROPLASTY USING A DEPUY TOTAL OR HEMI SHOULDER SYSTEM	The investigator has a significant financial interest in the study sponsor Depuy Synthes.	yes	Depuy Synthes Mitek	\$20,000 to \$39,999	no			no	
CRV_00172975	Benjamin Steinberg	Principal Investigator	IRB_00147440	Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS Registry)	The investigator reports a significant financial interest in AltaThera, the study sponsor.	yes	AltaThera	\$5,000 to \$9,999	no			no	
CRV_00173000	Michael Flynn	Key Personnel	IRB_00128991	Design, Implementation and Evaluation of Scalable Decision Support for Chronic Disease Management and Health Maintenance	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00173204	Christopher Pelt	Principal Investigator	IRB_00075446	Clinical and Biomechanical Outcomes Following Total Knee Arthroplasty	The investigator's financial interests may be related to the broad aims of this research.	yes	Total Joint Orthopaedics; Smith and Nephew	\$20,000 to \$39,999 \$5,000 to \$9,999	yes	Joint Development, Inc.	Value cannot be readily determined	no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00173279	Zachary Hillman	Data Analyst	IRB_00110994	Transcutaneous Stimulation for Haptic Feedback	The investigator reports significant financial interest with the Biological Input Output Systems, which will be involved in the study.	yes	Biological Input Output Systems	\$10,000 to \$19,999	no			no	
CRV_00173708	Gregory Clark	Co-Investigator	IRB_00124231	Can an array of micro-electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device? (HAPTIX FDA IDE Approval)	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00174325	Florian Solzbacher	Co-Investigator	10065133	PASSIVE INTRACRANIAL PRESSURE SENSOR FOR HYDROCEPHALUS SHUNTS AND CRANIOPLASTY IMPLANTS WITH ULTRASOUND READOUT	The investigator's intellectual property is being used in the study. The technology has been licensed to Sentiomed, a non-publicly traded company in which the investigator reports a significant financial interest. Sentiomed is a sponsor of this project.	no			yes	Sentiomed	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00175075	Mark Yandell	Co-Investigator	IRB_00142987	ReSeq: Reanalysis of clinical rapid whole genomes	The investigator's intellectual property will be used in the study. The investigator reports a significant financial interest in Fabric Genomics and Backdrop Heath, companies which have licensed the technology.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics Backdrop Health Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00175088	Jill Shea	Principal Investigator	10065448	SUPPLEMENT: DEVELOPMENT OF A NOVEL SUSTAINED RELEASE LOCAL ANESTHETIC WOUND DRESSING FOR PARTIAL-THICKNESS DERMAL INJURIES	The investigator reports a significant financial interest with the study sponsor, Rebel Medicine.	no			yes	Rebel Medicine	Value cannot be readily determined	no	
CRV_00175098	ALANA WELM	Principal Investigator	IRB_00156327	Development and use of patient-derived xenograft and organoid models	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00175099	Bryan Welm	Co-Investigator	IRB_00156327	Development and use of patient-derived xenograft and organoid models	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00175154	Nathan Hatton	Co-Investigator	IRB_00132922	A Phase I/II Randomized Double-Blinded Placebo-Controlled Clinical Trial to Determine Safety and Feasibility of Using an Acellular Sterile Filtered Amniotic Fluid as a Treatment for COVID-19 Patients	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00175438	Bryan Welm	Co-Investigator	10062203	VALIDATION OF THE MHC II IMMUNE ACTIVATION ASSAY IN BREAST CANCER	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00176732	Daniel Scoles	Co-Investigator	IRB_00092440	Genetic, Biological and Functional Studies of Neurodegenerative Diseases	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00177616	ALANA WELM	Principal Investigator	10061993	PREVENTION OF LETHAL METASTATIC BREAST CANCER BY IDENTIFYING AND ERADICATING CLINICALLY RELEVANT DISSEMINATED TUMOR CELLS	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00178032	Bryan Welm	Principal Investigator	10047239	LONGITUDINAL MODELS OF BREAST CANCER FOR STUDYING MECHANISMS OF THERAPY RESPONSE AND RESISTANCE	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00178168	ALANA WELM	Principal Investigator	10047239	LONGITUDINAL MODELS OF BREAST CANCER FOR STUDYING MECHANISMS OF THERAPY RESPONSE AND RESISTANCE	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00178288	Gabor Marth	Principal Investigator	10062720	A WEB-BASED PLATFORM TO SUPPORT TEAM-BASED GENOME DIAGNOSTICS	The investigator's intellectual property is being used in the study. It has been exclusively licensed to Frameshift Labs (the study sponsor), a non-publicly traded company in which the investigator reports a significant financial interest.	no			yes	Frameshift Labs, LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00178735	JUSTIN ENGLISH	Principal Investigator	10058882	DIRECTED EVOLUTION OF CELL-TYPE SPECIFIC ON-DEMAND SIGNALING CONTROL SYSTEMS	The investigator's licensed intellectual property is being used in the project. The investigator reports a significant financial interest in Evolution Bio, the licensor of the technology.	yes	Evolution Bio	\$10,000 to \$19,999	yes	Evolution Bio	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00178955	Josef Stehlik	Co-Investigator	IRB_00157198	DevelopmEnt of non-invasive cell-Free DNA to supplant InvasivE biopsy in Heart Transplantation (DEFINE-HT)	The investigator reports a significant financial interest in the study sponsor, Natera.	yes	Natera	\$20,000 to \$39,999	no			no	
CRV_00179292	Eric Garland	Principal Investigator	10063568	MORE CLBP R01: ANALGESIC AND OPIOID SPARING BRAIN MECHANISMS OF MINDFULNESS-ORIENTED RECOVERY ENHANCEMENT FOR CHRONIC LOW BACK PAIN	The investigator's intellectual property in being used in the study. The investigator reports a significant financial interest in the licensor of the technology, BehaVR.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00179389	Tommaso Lenzi	Principal Investigator	10052902	NRI: INT: COLLAB: VOLITIONAL CONTROL OF ROBOTIC LEG PROSTHESES WITH SONOMYOGRAPHIC SENSING	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00179393	Tommaso Lenzi	Principal Investigator	10056011	LIGHTWEIGHT POWERED KNEE-ANKLE PROSTHESIS FOR COMMUNITY AMBULATION	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00179395	Tommaso Lenzi	Principal Investigator	IRB_00103197	Lightweight Motorized Prostheses for Lower-limb Amputees	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00180202	ALANA WELM	Co-Investigator	IRB_00153239	TOWARDS II: Towards Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of Triple Negative Breast Cancer	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00181282	ALANA WELM	Co-Investigator	IRB_00010924	Molecular Classifications of Cancer	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00181334	Mark Yandell	Co-Investigator	IRB_00057688	A Personalized Medicine Program and Quality Improvement Initiative in Cardiac Dysrhythmias	The investigator's intellectual property is being used in the study. The investigator reports significant financial interest with Fabric Genomics and Backdrop Health, the licensors of the technology.	yes	Backdrop Health Inc. Fabric Genomics	Zero to \$4,999 \$80,000 to \$99,999	yes	Backdrop Health Inc. Fabric Genomics	Value cannot be readily determined Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00182217	Eric Garland	Co-Investigator	IRB_00159762	Physical Therapy Integrated with Mindfulness for Patients with Chronic Musculoskeletal Pain and Long-Term Opioid treatment	The investigator's intellectual property will be used in the study. This intellectual property is licensed through BehaVR, a company with which the investigator reports significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00182575	Miti Shum	Principal Investigator	IRB_00158126	GSK_217013 - A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hyper eosinophilic Syndrome (HES)	The investigator reports significant financial interest in GSK (Glaxo Smith Kline), the company that makes the study drug Depemokimab.	yes	GSK (Glaxo Smith Kline)	\$5,000 to \$9,999	no			no	
CRV_00182678	Mary Scholand	Principal Investigator	IRB_00158413	1305-0014 (FIBRONEER-IPF): A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks inpatients with Idiopathic Pulmonary Fibrosis (IPF)	The investigator reports significant financial interest in the study sponsor, Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00182680	Mary Scholand	Principal Investigator	IRB_00158440	1305-0023 (FIBRONEER-ILD): A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 weeks inpatients with Progressive Fibrosing Interstitial Lung Diseases(PF-ILDs)	The investigator reports significant financial interest in the study sponsor, Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00182924	Peter Chalmers	Principal Investigator	IRB_00158548	Orthopaedic Shoulder Joint Replacement Surgical Outcomes Registry - DePuy	The investigator reports significant financial interest in the study sponsor Depuy Synthes.	yes	Depuy Synthes	\$20,000 to \$39,999	no			no	
CRV_00182991	Michael Free	Principal Investigator	10060902	EXTRACTION, SEPARATION, AND PRODUCTION OF HIGH PURITY RARE EARTH ELEMENTS AND CRITICAL MINERALS FROM COAL-BASED AND RELATED RESOURCES	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00182995	Michael Free	Principal Investigator	10060158	TRANSFORMING UINTA BASIN EARTH MATERIALS FOR ADVANCED PRODUCTS (TUBE-MAP)	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00183233	Mary Scholand	Co-Investigator	IRB_00148442	ENDCOV-I: Early Nintedanib Deployment in COVID-19 Interstitial Lung Disease	The investigator reports significant financial interest in the drug manufacturer Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00184398	Mili Shum	Principal Investigator	10066106	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DEPEMOKIMAB IN ADULTS WITH HYPEREOSINOPHILIC SYNDROME (HES)	The investigator reports significant financial interest in GSK (Glaxo Smith Kline), the manufacturer of the study drug Depemokimab.	yes	GSK (Glaxo Smith Kline)	\$5,000 to \$9,999	no			no	
CRV_00184470	Kent Bachus	Co-Investigator	IRB_00149558	Biomechanical adaptations after transfemoral and transhumeral amputation	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00184980	Eric Garland	Principal Investigator	10064492	PHYSICAL THERAPY WITH INTIGRATED MINDFULNESS FOR PATIENTS WITH CHRONIC MUSCULOSKELETAL PAIN AND LONG TERM OPIOID TREATMENT	The investigator's intellectual property will be used in the study. This intellectual property is licensed through BehaVR, a company with which the investigator reports significant financial interest.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00185249	Josef Stehlik	Principal Investigator	IRB_00149853	The INTERHEART DD-cfDNA-HLA calibration study	The investigator reports a significant financial interest in Natera Inc., the manufacturer of the Prospera test being used in the study.	yes	Natera	\$20,000 to \$39,999	no			no	
CRV_00185291	ALISTAIR WARD	Co-Investigator	IRB_00142987	ReSeq: Reanalysis of clinical rapid whole genomes	The investigator's intellectual property is being used in the study. The investigator reports a significant financial interest in Frameshift Labs, the licensor of the technology.	yes	Frameshift Labs, Inc	Over \$100,000	yes	Frameshift Labs, Inc	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00185354	ALISTAIR WARD	Co-Investigator	IRB_00125940	The Utah NeoSeq Project	The investigator's intellectual property is being used in the study. The investigator reports a significant financial interest in Frameshift Labs, the company which licenses the technology.	yes	Frameshift Labs, Inc	Over \$100,000	yes	Frameshift Labs, Inc	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00185492	Eric Schmidt	Principal Investigator	10064060	ORIGIN OF CHEMICAL DIVERSITY IN THE ANIMALS	The investigator's intellectual property is being used in the project. The investigator reports a significant financial interest in Synthetic Biodesign, the licensor of the technology.	no			yes	Synthetic Biodesign	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00185495	Christopher Gregg	Co-Investigator	IRB_00152312	PAPR: Psilocybin-Assisted Psychotherapy + Mindfulness-Based Stress Reduction (MBSR) for front-line healthcare provider COVID-19 related burnout.	The investigator reports significant financial interest in Storyline Health, a company which provides the platform for collecting study data.	yes	Storyline Health	Zero to \$4,999	yes	Storyline Health	Value cannot be readily determined	no	
CRV_00185908	Kerry Kelly	Principal Investigator	IRB_00163507	Interviews to Support: Community Resilience through Engaging, Actionable, Timely, High-Resolution Air Quality Information (CREATE-AQI)	The investigator reports significant financial interest in Tellus Networked Sensor Solutions Inc, a company providing the sensors for the project.	yes	Tellus Networked Sensor Solutions, Inc	\$10,000 to \$19,999	yes	Tellus Networked Sensor Solutions, Inc	Value cannot be readily determined	no	
CRV_00186002	Marshall Smith	Principal Investigator	10068086	SUBGLOTTAL STENOSIS (SGS) AND VOCAL FOLD INJURY WITH ENDOWMENT FUNDS	This investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00186185	Mark Yandell	Co-Investigator	IRB_00108137	Rapid Sequencing in Acutely Ill Children	The investigator's licensed intellectual property will be used in the project. The investigator has a significant financial interest in Fabric Genomics, the licensor of the technology.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00186186	Brook Martin	Principal Investigator	IRB_00164316	Validating the Accuracy and Usability of a Mobile Device App for Collecting Patient Reported Outcomes.	The investigator has significant financial interest in Statix, LLC, a company providing the electronic patient-reported outcome mobile app platform for this project.	yes	STATIX, LLC	\$80,000 to \$99,999	yes	STATIX, LLC	Value cannot be readily determined	no	
CRV_00186443	K-T VARLEY	Principal Investigator	IRB_00164550	Prevention of Lethal Metastatic Breast Cancer by Identifying and Eradicating Clinically Relevant Disseminated Tumor Cells; Project 5: Defining actionable epigenetic variants in clinically relevant disseminated tumor cells	The investigator's intellectual property with be used in the study. The investigator reports a significant financial interest with Kalos Genetics, the licensor of the technology.	yes	Kalos Genetics	\$20,000 to \$39,999	yes	Kalos Genetics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00187129	John Ryan	Principal Investigator	IRB_00157579	A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients (HYPERION)	The investigator reports significant financial interest in Merck, the parent company of the study sponsor Acceleron.	yes	Merck Sharp & Dohme	\$40,000 to \$59,999	no			no	
CRV_00187265	John Ryan	Principal Investigator	10066194	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE SOTATERCEPT WHEN ADDED TO BACKGROUND PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPY IN NEWLY DIAGNOSED INTERMEDIATE- AND HIGH-RISK PAH PATIENTS	The investigator reports significant financial interest in Merck, the parent company of the study sponsor Acceleron.	yes	Merck Sharp & Dohme	\$40,000 to \$59,999	no			no	
CRV_00187455	John Ryan	Principal Investigator	10064987	MACITENTAN IN INOPERABLE OR PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION	The investigator reports significant financial interest in Janssen, the study sponsor.	yes	Janssen Pharmaceuticals	\$80,000 to \$99,999	no			no	
CRV_00187915	Glenn Sjoden	Principal Investigator	10068585	WSU XENON OPTIMIZATION - PHASE II	The investigator's intellectual property will be used in the project. The investigator reports a significant financial interest in HSW Technologies, LLC, a non-publicly traded company which has licensed the technology.	no			yes	HSW Technologies, LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00187992	Steffen Schmitz-Vatkenberg	Principal Investigator	IRB_00164875	Real-World, Long-Term Data Collection To Gain Clinical Insights Into Roche Ophthalmology Products (VOYAGER STUDY)	The investigator reports significant financial interest in the Roche/Genentech, which is the manufacturer of products used in this project.	yes	Roche/Genentech	\$5,000 to \$9,999	no			no	
CRV_00188348	MARK CLEMENT	Principal Investigator	10068225	PAN-DISEASE CHARACTERIZATION OF DNA METHYLATION DYSREGULATION	The investigator reports a significant financial interest in Edilytics, Inc, a non-publicly traded company which has licensed the investigator's intellectual property being used in the project.	yes	Edilytics, Inc.	Over \$100,000	yes	Edilytics, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00188422	JAMIE DWYER	Principal Investigator	10065093	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP, DOSE-RANGING STUDY TO EVALUATE CIN-10 FOR THE TREATMENT OF PATIENTS WITH UNCONTROLLED HYPERTENSION AND CHRONIC KIDNEY DISEASE - CIN-107	The investigator reports significant financial interest in the AstraZeneca, the parent company of the study sponsor Cincor.	yes	AstraZeneca Pharmaceuticals	\$10,000 to \$19,999	no			no	
CRV_00188428	JAMIE DWYER	Principal Investigator	IRB_00153012	A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group, Dose-Ranging Study to Evaluate CIN-107 for the Treatment of Patients With Uncontrolled Hypertension and Chronic Kidney Disease	The investigator reports significant financial interest in the AstraZeneca, the parent company of the study sponsor Cincor.	yes	AstraZeneca Pharmaceuticals	\$10,000-19,000	no			no	
CRV_00188495	Mary Beth Scholand	Principal Investigator	IRB_00162671	RIN-PF-302 (TETON OLE): An Open-label Extension Study of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis	The investigator reports significant financial interest in the study sponsor United Therapeutics.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00188512	Mary Beth Scholand	Principal Investigator	10066630	A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BI 1015550 OVER AT LEAST 52 WEEKS IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)	The investigator reports significant financial interest in the study sponsor, Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00188517	Mary Beth Scholand	Principal Investigator	10067252	A DOUBLE BLIND, RANDOMIZED, PLACEBO-CONTROLLED TRIAL EVALUATING THE EFFICACY AND SAFETY OF BI 1015550 OVER AT LEAST 52 WEEKS IN PATIENTS WITH PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASES (PF-ILDs)	The investigator reports significant financial interest in the study sponsor, Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00188530	Mary Beth Scholand	Principal Investigator	10059343	A PHASE III OPEN-LABEL EXTENSION STUDY TO EVALUATE LONG-TERM SAFETY AND EFFICACY OF PRM-151 IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF)	The investigator reports significant financial interest in Genentech, the study sponsor and manufacturer.	yes	Genentech	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00188537	Mary Beth Scholand	Principal Investigator	10055620	STUDY OF THERAPEUTIC PLASMA EXCHANGE, RITUXIMAB, AND INTRAVENOUS IMMUNOGLOBULIN FOR ACUTE EXACERBATIONS OF IDIOPATHIC PULMONARY FIBROSIS	The investigator reports significant financial interest in Genentech, which produces a medication used in the project.	yes	Genentech	\$5,000 to \$9,999	no			no	
CRV_00188541	Mary Beth Scholand	Principal Investigator	10067591	AN OPEN-LABEL EXTENSION STUDY OF INHALED TREPROSTINIL IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS	The investigator reports significant financial interest in the study sponsor United Therapeutics.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00188568	Mary Beth Scholand	Principal Investigator	IRB_00126303	STRIVE-IPF: Study of Therapeutic Plasma Exchange, Rituximab, and Intravenous Immunoglobulin for Acute Exacerbations of Idiopathic Pulmonary Fibrosis	The investigator reports significant financial interest in Genentech, which produces a medication used in the project.	yes	Genentech	\$5,000 to \$9,999	no			no	
CRV_00188859	Claude Nanjo	Co-Investigator	IRB_00134238	Design, Implementation and Evaluation of Scalable Decision Support for Diabetes Care	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00189040	John Ryan	Principal Investigator	IRB_00165318	RESONANCE-RegStry Of the Natural history of recurrenceNt pericarditis in pEdiatric and adult patients	The investigator reports significant financial interest in the study sponsor Kiniksa Pharmaceuticals.	yes	Kliniksa	\$20,000 to \$39,999	no			no	
CRV_00189222	Mark Yandell	Co-Investigator	10066059	TOWARDS PRECISION MEDICINE FOR THORACIC AORTIC DISEASE: DEFINING THE CLINICAL AND GENOMIC DRIVERS OF Bicuspid Aortopathy	The investigator's intellectual property will be used in the project. The technology is licensed by Backdrop Health, a non-publicly traded company in which the investigator reports significant financial interest.	yes	Backdrop Health Inc.	Zero to \$4,999	yes	Backdrop Health Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00189464	K-T VARLEY	Principal Investigator	10062012	PREVENTION OF LETHAL METASTATIC BREAST CANCER BY IDENTIFYING AND ERADICATING CLINICALLY RELEVANT DISSEMINATED TUMOR CELLS	The investigator's intellectual property with be used in the study. The investigator reports a significant financial interest with Kallos Genetics, the licensor of the technology.	yes	Kallos Genetics Inc	\$20,000 to \$39,999	yes	Kallos Genetics Inc	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00189482	BENJAMIN SANCHEZ TERRONES	Principal Investigator	IRB_00162369	Wearable Sensor Blood Pressure Study	The investigator reports significant financial interest in the study sponsor B-Secur.	yes	B-Secur	\$5,000 to \$9,999	yes	B-Secur	Value cannot be readily determined	no	
CRV_00189635	MICHAEL JOHNSON	Co-Investigator	10069130	VENTRIGHT PO: MHRF IDIQ SUBCONTRACT SC-19-05	The investigator's intellectual property will be used in the project. The investigator reports significant financial interest in Certus Critical Care, Inc, the company that licenses the technology.	no			yes	Certus Critical Care, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00189912	Marvin Moore	Other	IRB_00076995	The Genetics of Primary Ovarian Insufficiency	The investigator's intellectual property will be used. The investigator also reports significant financial interest in the company, Fabric Genomics, that licenses the intellectual property.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00190121	Ramesh Grandhi	Co-Investigator	IRB_00131046	EVOLVE: EndoVascular Treatment Of Wide-Neck Aneurysms, an Evaluation of Safety and Effectiveness of Stryker Surpass valve® Flow Diverter System	The investigator reports significant financial interest in the study sponsor Stryker.	yes	Stryker Neurovascular	\$10,000 to \$19,999	no			no	
CRV_00190304	Marvin Moore	Other	IRB_00007551	Clinical Genetics Research Program	The investigator's licensed intellectual property will be used in the project. The investigator reports significant financial interest in Fabric Genomics, the licensor of the technology.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00190323	Allison Payne	Principal Investigator	IRB_00114506	Validation of a Protocol for a Non-Invasive, Magnetic Resonance Guided Breast Cancer Therapy	The investigator's intellectual property is being used in the study. The technology has been non-exclusively licensed to Image Guided Therapeutics.	no			no			yes	Value cannot be readily determined
CRV_00190361	Mary Beth Scholand	Principal Investigator	IRB_00143600	RIN-PF-301 (TETON): A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Idiopathic Pulmonary Fibrosis	The investigator reports significant financial interest with United Therapeutics, the study sponsor.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00190363	Mary Beth Scholand	Principal Investigator	10061442	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF INHALED TREPROSTINIL IN SUBJECTS WITH IDIOPATHIC PULMONARY FIBROSIS	The investigator reports significant financial interest in United Therapeutics, the study sponsor.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00191024	Peter Chalmers	Principal Investigator	IRB_00168285	Mitek Sports Clinical Outcomes Registry (MS-CORE)	The investigator reports significant financial interest in the study co-sponsor DePuy Synthes Mitek.	yes	DePuy Synthes Mitek	\$20,000 to \$39,999	no			no	
CRV_00191056	Reid Robison	Principal Investigator	IRB_00168289	Group Ketamine-Assisted Therapy Using Internal Family Systems: An Exploratory Study	The investigator reports significant financial interest in Numinus, the clinic at which participants were seen.	no			yes	Numinus	Value cannot be readily determined	no	
CRV_00191057	Reid Robison	Principal Investigator	IRB_00168306	Group Ketamine-Assisted Therapy Using Internal Family Systems: An Extension Study	The investigator reports significant financial interest in Numinus, the clinic at which participants were seen.	no			yes	Numinus	Value cannot be readily determined	no	
CRV_00191278	Peter Chalmers	Principal Investigator	10067772	MITEK DEVICE REGISTRY	The investigator reports significant financial interest in the study sponsor DePuy Synthes Mitek.	yes	DePuy Synthes Mitek	\$20,000 to \$39,999	no			no	
CRV_00191682	Christopher Gregg	Other	IRB_00165240	Storyline KAP: Deep AI Behavioral Profiling to Reveal Mental and Behavioral Phenotypes Shaping Outcomes with Ketamine-Assisted Psychotherapy	The investigator reports significant financial interest in Storyline Health, a non-publicly traded company which owns the technology being evaluated in this project.	no			yes	Storyline Health	Value cannot be readily determined	no	
CRV_00191929	Stefan Niederauer	Principal Investigator	IRB_00168563	Ergonomic Assessment of an Ambulatory Pelvic Floor Biofeedback Device	The investigator reports significant financial interest in Freyya, Inc., a company which owns the device being evaluated in the study.	no			yes	Freyya, Inc.	Value cannot be readily determined	no	
CRV_00192376	Shiven Patel	Co-Investigator	IRB_00124882	Osi + Ipi: A Phase Ib Study to Evaluate the Safety and Efficacy of Osimertinib in Combination with Ipilimumab in Patients with EGFR Mutated Non-Small-Cell Lung Cancer Tumors	The investigator reports significant financial interest in Astrazeneca, the manufacturer of Osimertinib, one of the medications being used in the project.	yes	Astrazeneca	\$5,000 to \$9,999	no			no	
CRV_00192403	Shiven Patel	Co-Investigator	IRB_00114610	ETCTN 10042 (CIRB)>>A Phase II trial of AZD9291 (osimertinib)with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases	The investigator reports significant financial interest in Astrazeneca, the company which manufactures the study drug AZD9291(Osimertinib).	yes	Astrazeneca	\$5,000 to \$9,999	no			no	
CRV_00192409	Shiven Patel	Co-Investigator	IRB_00137469	ETCTN 10216 (CIRB)>> A Phase I/II Study of AZD9291 (Osimertinib) and CB-839 HCl in Patients with EGFR Mutant Non-Small Cell Lung Cancer	The investigator reports significant financial interest in Astrazeneca, the company which manufactures the study drug AZD9291(Osimertinib).	yes	Astrazeneca	\$5,000 to \$9,999	no			no	
CRV_00192776	Ling Zang	Principal Investigator	10069679	FLUORESCENCE-SOLID PHASE EXTRACTION (F-SPE) PLATFORM FOR RAPID, ON-SITE DETECTION OF PFAS --- SUBCONTRACT TO UU	The investigator's intellectual property will be used in the project. Commercialization is imminent with Novus Analytical Technologies, a company in which the investigator reports a significant financial interest.	no			yes	Novus Analytical Technologies	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00193058	John Ryan	Other	10066225	AN OPEN-LABEL LONG-TERM FOLLOW-UP STUDY TO EVALUATE THE EFFECTS OF SOTATERCEPT WHEN ADDED TO BACKGROUND PULMONARY ARTERIAL HYPERTENSION (PAH) THERAPY FOR THE TREATMENT OF PAH	The investigator reports significant financial interest in Merck Sharp & Dohme, the parent company of the study sponsor.	yes	Merck Sharp & Dohme	\$40,000 to \$59,999	no			no	
CRV_00193481	Steffen Schmitz-Valkenberg	Principal Investigator	10068020	REAL-WORLD, LONG-TERM DATA COLLECTION TO GAIN CLINICAL INSIGHTS INTO ROCHE OPHTHALMOLOGY PRODUCTS	The investigator reports significant financial interest in Roche, the manufacturer of Faricimab.	yes	Roche	\$5,000 to \$9,999	no			no	
CRV_00193681	Allison Payne	Principal Investigator	10069874	VALIDATION AND TRANSLATION OF A NON-INVASIVE, MR-GUIDED BREAST CANCER THERAPY	The investigator's intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00193788	John Ryan	Principal Investigator	IRB_00158086	An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH (SOTERIA)	The investigator reports significant financial interest in Merck Sharp & Dohme, the parent company of the study sponsor.	yes	Merck Sharp & Dohme	\$40,000 to \$59,999	no			no	
CRV_00193809	Glenn Sjoden	Principal Investigator	10069326	133MXE PRODUCTION TUNING CAMPAIGN	The investigator's intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00194068	Dennis Parker	Co-Investigator	10057016	ADVANCED TREATMENT ENDPOINT ASSESSMENT IN MR-GUIDED FOCUSED ULTRASOUND	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00194076	Dennis Parker	Principal Investigator	10051590	TOWARD THE NEXT GENERATION IN TRANSCRANIAL MR-GUIDED FOCUSED ULTRASOUND: INNOVATIONS IN THERMAL AND ACOUSTIC MODEL-BASED PLANNING AND MONITORING FOR IMPROVED SAFETY, EFFICACY AND EFFICIENCY	The investigator's intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00194562	Eric Garland	Principal Investigator	10067015	OPTIMIZING PATIENT-CENTERED OPIOID TAPERING WITH MINDFULNESS-ORIENTED RECOVERY ENHANCEMENT	The investigator holds a significant financial interest through self-employment that is related to the project.	yes	Self Employment	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00194651	Phillip Warner	Co-Investigator	IRB_00134238	Design, Implementation and Evaluation of Scalable Decision Support for Diabetes Care	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00195041	Eric Garland	Principal Investigator	IRB_00161776	Motivational Interviewing (MI) and Mindfulness-Oriented Recovery Enhancement (MORE) for Tobacco Dependence and Other Drug use in Methadone Treatment	The investigator reports significant financial interest in BehaVR, a non-publicly traded company which has licensed the investigator's intellectual property used in this project.	yes	BehaVR	\$10,000 to \$19,999	no			yes	Value cannot be readily determined
CRV_00195145	Allie Fredbo	Principal Investigator	IRB_00170147	Explosives Use and Blast Overpressure Exposure of Avalanche Mitigation Workers	The investigator reports significant financial interest from Park City Mountain Resort, which is one of the sites participating in the study.	yes	Park City Mountain Resort	\$20,000 to \$39,999	no			no	
CRV_00195641	Mark Yandell	Principal Investigator	IRB_00167500	sIRB: Congenital Heart Disease Genetic Network (CHD Genes)	The investigator's intellectual property will be used in the project. The investigator reports significant financial interest in the companies that license these intellectual properties.	yes	Fabric Genomics	\$80,000 to \$99,999	yes	Fabric Genomics Backdrop Health Inc.	Value cannot be readily determined Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00197064	TINGTING HONG	Principal Investigator	10066751	CORRECTING CARDIAC MICRODOMAINS REVERSES NON-ISCHEMIC CARDIOMYOPATHY	The investigator's intellectual property will be used in the project. The investigator reports significant financial interest in TikkunLev Therapeutics, a non-publicly traded company which licenses the intellectual property being used.	no			yes	TikkunLev Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00197065	ROBIN SHAW	Principal Investigator	10066751	CORRECTING CARDIAC MICRODOMAINS REVERSES NON-ISCHEMIC CARDIOMYOPATHY	The investigator's intellectual property will be used in the study. The investigator reports significant financial interest in TikkunLev Therapeutics, the company that licenses these intellectual properties.	no			yes	TikkunLev	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00197066	Florian Solzbacher	Co-Investigator	10069109	HIGH-DENSITY CHRONIC OPTOGENETIC INTERFACE FOR PRIMATE BRAINS	The investigator's intellectual property, licensed to the study sponsor Blackrock Microsystems, will be used in the study. The investigator reports significant financial interest in Blackrock Microsystems.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00197382	RANDALL PETERSON	Principal Investigator	10067612	ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS	The investigator's licensed intellectual property will be used in the project.	no			yes	InVivo Biosystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00197385	RANDALL PETERSON	Principal Investigator	10051526	ADVANCING GENE-EDITING NUCLEASES FOR DIVERSE ZEBRAFISH APPLICATIONS	The investigator's licensed intellectual property will be used in the project.	no			yes	InVivo Biosystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00197387	RANDALL PETERSON	Principal Investigator	10062988	IN VIVO FUNCTIONAL SCREEN OF NONCODING GENETIC ELEMENTS	The investigator's intellectual property will be used in the project.	no			yes	InVivo Biosystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00197410	Jamie Rhoads	Principal Investigator	IRB_00167413	BI 1368-0098 - Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa. Lunsayil 1.	The investigator reports significant financial interest in Boehringer Ingelheim Pharmaceuticals, Inc., the study sponsor.	yes	Boehringer Ingelheim Pharmaceuticals, Inc.	\$5,000 to \$9,999	no			no	
CRV_00197432	Kerry Kelly	Principal Investigator	10069923	AIR QUALITY SENSOR CALBRATION	The investigator reports significant financial interest in Tellus Networked Sensor Solutions, Inc., the study sponsor.	yes	Tellus Networked Sensor Solutions, Inc.	\$10,000 to \$19,999	yes	Tellus Networked Sensor Solutions, Inc.	Value cannot be readily determined	no	
CRV_00198162	Gabor Marth	Other	10068928	A STATE-OF-THE-ART WEB PLATFORM FOR COLLABORATIVE, LONGITUDINAL GENOME DIAGNOSTICS	The investigator's intellectual property will be used in the project. The technology is licensed by the study sponsor, Frameshift Labs, Inc., a privately traded company with which the investigator reports significant financial interest.	no			yes	Frameshift Labs, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00198212	LAWRENCE CARR	Other	IRB_00168602	Photobiomodulation and Integrative Health Treatment in Veterans: A Pilot Study	The investigator reports significant financial interest in Vielight, Inc., the manufacturer of the investigational medical device used in this study.	yes	Vielight, Inc	\$10,000 to \$19,999	no			no	
CRV_00198644	Henrik Odeen	Principal Investigator	10057016	ADVANCED TREATMENT ENDPOINT ASSESSMENT IN MR-GUIDED FOCUSED ULTRASOUND	The investigator's intellectual property will be involved in this project.	no			no			yes	Value cannot be readily determined
CRV_00198809	Gregory Hageman	Principal Investigator	10034394	Drug Targets, Therapeutics and Diagnostics for the Treatment of AMD	The investigator's licensed intellectual property will be used in the study. The investigator reports significant financial interest in Perceive Therapeutics (formerly known as Voyant Therapeutics), the study sponsor and company which licenses these intellectual properties.	yes	Perceive Therapeutics, Inc.	Over \$100,000	yes	Perceive Therapeutics, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00199713	ALANA WELM	Principal Investigator	10067419	PDX TRIAL CENTER FOR BREAST CANCER THERAPY	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00199915	Bryan Welm	Co-Investigator	10067419	PDX TRIAL CENTER FOR BREAST CANCER THERAPY	Models generated by this project may be imminently licensed as tangible property.	no			no			yes	Value cannot be readily determined
CRV_00200695	Tom Riis	Other	IRB_00162656	Ultrasonic brain stimulation for generalized chronic pain: A pilot study of target engagement and analgesic effects	The investigator reports significant financial interest in Spire Therapeutics, a privately traded company that licenses a device being used in this project.	no			yes	Spire Therapeutics	Value cannot be readily determined	no	
CRV_00200937	Julia Batten	Other	IRB_00100769	A Phase II Open Label Single Arm Study of Adjuvant Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT)	The investigator reports significant financial interest in the study sponsor Bristol-Meyers Squibb.	yes	Bristol-Meyers Squibb	\$5,000 to \$9,999	no			no	
CRV_00200950	Julia Batten	Other	IRB_00154048	Bayer 20321 (sIRB) >> An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies	The investigator reports significant financial interest in the study sponsor Bayer Pharmaceuticals.	yes	Bayer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00200962	Julia Batten	Other	IRB_00159613	Duke Cancer Institute Pro00107408 >> Outcomes Database to prospectively aSSess the changing TherapY landscape in Renal Cell Carcinoma (ODYSSEY RCC)	The investigator reports significant financial interest in the study sponsor Bristol-Meyers Squibb.	yes	Bristol Meyers Squibb	\$5,000 to \$9,999	no			no	
CRV_00201203	Mary Beth Scholand	Co-Investigator	IRB_00169643	PHINDER: Pulmonary Hypertension Screening in Patients with Interstitial Lung Disease for Earlier Detection	The investigator reports significant financial interest in United Therapeutics, the study sponsor.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00201423	Christos Vakilavas	Co-Investigator	10055305	TALAVE: A PILOT TRIAL OF INDUCTION TALAZOPARIB FOLLOWED BY COMBINATION OF TALAZOPARIB AND AVELUMAB IN ADVANCED BREAST CANCER	The investigator reports significant financial interest in Pfizer, which manufactures one of the study medications.	yes	Pfizer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00201424	Christos Vakilavas	Co-Investigator	IRB_00169920	Relay Therapeutics RLY-5836-101 (sIRB) >> A First-in-Human Study of PI3Ka Inhibitor, RLY-5836, in Combination with Targeted and Endocrine Therapies in Participants with Advanced Breast Cancer and as a Single Agent in Advanced Solid Tumors	The investigator reports significant financial interest in Pfizer, the manufacturer of one of the medications (palbociclib) used in the project.	yes	Pfizer Pharmaceuticals	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00201432	Christos Vakilavas	Co-Investigator	IRB_00099894	Alliance Foundation Trials AFT-38>>A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy after Induction Treatment for Hormone Recept	The investigator reports significant financial interest in Pfizer, which manufactures one of the study medications (palbociclib).	yes	Pfizer	\$5,000 to \$9,999	no			no	
CRV_00201433	Christos Vakilavas	Co-Investigator	IRB_00117145	Alliance A171601 (CIRB)>>A phase II trial assessing the tolerability of palbociclib in combination with letrozole or fulvestrant in patients aged 70 and older with estrogen receptor-positive, HER2-negative metastatic breast cancer	The investigator reports significant financial interest in Pfizer, which manufactures one of the study medications (palbociclib).	yes	Pfizer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00201439	Christos Vakilavas	Co-Investigator	IRB_00126991	Georgetown IIT TALAVE 00000023>>TALAVE: A pilot trial of induction talazoparib followed by combination of talazoparib and avelumab in advanced breast cancer	The investigator reports significant financial interest in Pfizer, which manufactures one of the study medications.	yes	Pfizer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00201448	Christos Vakilavas	Co-Investigator	IRB_00133819	Northwestern University NU 15B06 (PROMISE) >> A large-scale multicenter phase II study evaluating the protective effect of a tissue selective estrogen complex (TSEC) in women with newly diagnosed ductal carcinoma in situ.	The investigator reports significant financial interest in Pfizer, which manufactures the study medication Duavee (conjugated estrogens/bazedoxifene).	yes	PFIZER INC	\$5,000 to \$9,999	no			no	
CRV_00202211	Eric Garland	Principal Investigator	IRB_00172836	Optimizing Patient-Centered Chronic Pain Care	The investigator holds a significant financial interest through self-employment that is related to the project.	yes	Self Employed	\$10,000 to \$19,999	no			no	
CRV_00202455	Kenneth Aston	Co-Investigator	10067917	NOVEL EPIGENETIC TEST FOR THE TREATMENT AND IMPROVEMENT OF LONGITUDINAL HEALTH-OUTCOMES FOR MEN WITH AZOOSPERMIA	The investigator reports significant financial interest in the study sponsor, Inherent Biosciences, Inc.	no			yes	Inherent Biosciences	Value cannot be readily determined	no	
CRV_00202456	James Hotaling	Principal Investigator	10067917	NOVEL EPIGENETIC TEST FOR THE TREATMENT AND IMPROVEMENT OF LONGITUDINAL HEALTH-OUTCOMES FOR MEN WITH AZOOSPERMIA	The investigator reports significant financial interest in the study sponsor, Inherent Biosciences, Inc.	no			yes	Inherent Biosciences, Inc	Value cannot be readily determined	no	
CRV_00202460	Jan Kubanek	Principal Investigator	IRB_00173062	Low-intensity Ultrasonic Brain Stimulation for Treatment of Post-Traumatic Stress Disorder	The investigator's licensed intellectual property will be used in the project. The investigator reports a significant financial interest in the licensor Spire Therapeutics.	no			no			yes	Value cannot be readily determined
CRV_00202683	Florian Solzbacher	Principal Investigator	10067881	COMMERCIAL TRANSLATION OF HIGH-DENSITY CARBON FIBER ELECTRODE ARRAYS FOR MULTI-MODAL ANALYSIS OF NEURAL MICROCIRCUITS	The investigator reports significant financial interest in the study sponsor Blackrock Microsystems.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00203203	Mary Beth Scholand	Principal Investigator	IRB_00173081	TETON-PPF: A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with Progressive Pulmonary Fibrosis	The investigator reports significant financial interest in United Therapeutics, the study sponsor.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00203324	Mary Beth Scholand	Principal Investigator	IRB_00171168	IM027068: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis	The investigator reports significant financial interest in Bristol Meyers Squibb, the study sponsor.	no			yes	BRISTOL-MYERS SQUIBB	\$40,000 to \$59,999	no	
CRV_00203421	Catherine Lee	Principal Investigator	IRB_00103515	A RANDOMIZED, DOUBLE-BLUNDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	The investigator's licensed intellectual property will be used in the study.	no			no			yes	Value cannot be readily determined
CRV_00203464	Mary Beth Scholand	Principal Investigator	IRB_00172671	GB44496 (Moonscape): A Two-Cohort, Phase II, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy and Safety of Vixarelimab Compared with Placebo in Patients with Idiopathic Pulmonary Fibrosis and in Pat	The investigator reports significant financial interest in Genentech, the sponsor for the study.	yes	Genentech	\$5,000 to \$9,999	no			no	
CRV_00203592	Mary Beth Scholand	Principal Investigator	IRB_00171171	IM0271015: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis	The investigator reports significant financial interest in Bristol Meyers Squibb, the study sponsor.	no			yes	BRISTOL-MYERS SQUIBB	\$40,000 to \$59,999	no	
CRV_00204062	Bryan Welm	Co-Investigator	10068933	OPTIMIZING QUANTITATIVE PHASE IMAGING FOR PREDICTING BREAST CANCER THERAPY RESPONSE	The investigators licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00204109	Nikola Markovic	Principal Investigator	10069989	MEASURING THE IMPACT OF ROADSIDE FEATURES ON ROAD-DEPARTURE CRASHES AND PRIORITIZING SAFETY IMPROVEMENT PROJECTS	The investigator's intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00204159	Daniel Couriel	Co-Investigator	IRB_00103515	A RANDOMIZED, DOUBLE-BLUNDED, PLACEBO-CONTROLLED STUDY FOR THE TREATMENT OF OCULAR CHRONIC GRAFT-VERSUS-HOST DISEASE (GVHD) WITH PROCESSED AMNIOTIC FLUID (pAF) DROPS	The investigator's intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00204226	Kensaku Kawamoto	Other	IRB_00175251	An Age-Friendly Learning Healthcare System: A Transformative Digital Solution for Geriatrics Clinics	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00204245	Jan Kubanek	Co-Investigator	IRB_00148802	Personalized ultrasonic brain stimulation for depression: A pilot study of target engagement and mood effects	The investigator's intellectual property will be used in the project. The investigator reports a significant financial interest with SPIRE Therapeutics, which licenses the intellectual property.	no			yes	Spire Therapeutic	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00204275	John Ryan	Principal Investigator	10068853	REGISTRY OF THE NATURAL HISTORY OF RECURRENT PERICARDITIS IN PEDIATRIC AND ADULT PATIENTS	The investigator reports significant financial interest in the study sponsor Kiniksa Pharmaceuticals.	yes	Kliniksa	\$20,000 to \$39,999	no			no	
CRV_00204375	Jan Kubanek	Principal Investigator	IRB_00174307	Low-Intensity Ultrasonic Brain Stimulation for Treatment of Post-Traumatic Stress Disorder	The investigator's intellectual property will be used in the project. The investigator reports a significant financial interest with SPIRE Therapeutics, which licenses the intellectual property.	no			yes	Spire Therapeutic	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00204376	Tom Riis	Other	IRB_00174307	Low-Intensity Ultrasonic Brain Stimulation for Treatment of Post-Traumatic Stress Disorder	The investigator reports significant financial interest in Spire Therapeutics. This privately traded company licenses intellectual property which will be used in the project.	no			yes	Spire Therapeutics	Value cannot be readily determined	no	
CRV_00204622	John Phillips	Co-Investigator	IRB_00036454	Birth Tissues for Translational Research Studies	The investigator reports that their intellectual properties, licensed by Etiksa Therapeutics, Inc., will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00204697	Christos Vakilavas	Co-Investigator	IRB_00088099	Alliance Foundation Trials AFT-05 >> PALLAS: Palbociclib CoLaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (	The investigator reports significant financial interest in Pfizer, which manufactures one of the study medications (Palbociclib).	yes	Pfizer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00204731	Claude Nanjo	Other	IRB_00175251	An Age-Friendly Learning Healthcare System: A Transformative Digital Solution for Geriatrics Clinics	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00204736	Mark Mahan	Principal Investigator	10067987	RENERVA/ NIH STTR: A NOVEL INJECTABLE, PERIPHERAL NERVE-SPECIFIC EXTRACELLULAR MATRIX-BASED HYDROGEL FOR IMPROVING FUNCTIONAL NERVE RECOVERY	The investigator reports significant financial interest in Renerva, the study sponsor.	no			yes	Renerva	Value cannot be readily determined	no	
CRV_00205125	Mary Beth Scholand	Principal Investigator	10069480	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BMS-986278 IN PARTICIPANTS WITH IDIOPATHIC PULMONARY FIBROSIS	The investigator reports significant financial interest in Bristol Meyers Squibb, the study sponsor.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00205126	Mary Beth Scholand	Principal Investigator	10070163	NINTEDANIB PLUS STANDARD OF CARE IMMUNOSUPPRESSION VERSUS STANDARD OF CARE IMMUNOSUPPRESSION ALONE IN PATIENTS WITH PROGRESSIVE FIBROTIC MYOSITIS ASSOCIATED - INTERSTITIAL LUNG DISEASE: A RANDOMIZED, DOUBLE-BLIND, EXPLORATORY TRIAL	The investigator reports significant financial interest in the study sponsor Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00205127	Mary Beth Scholand	Principal Investigator	10070505	A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF BMS-986278 IN PARTICIPANTS WITH PROGRESSIVE PULMONARY FIBROSIS	The investigator reports significant financial interest in Bristol Meyers Squibb, the study sponsor.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00205397	LAWRENCE CARR	Co-Investigator	IRB_00152001	Measurement of treatment effects of transcranial photobiomodulation on former athletes and Veterans with a history of repetitive head injuries	The investigator reports significant financial interest in VieLight, Inc., the study sponsor.	yes	Vielight, Inc	\$10,000 to \$19,999	no			no	
CRV_00205560	Jan Kubanek	Principal Investigator	IRB_00175583	Noninvasive targeted neuromodulation for treatment of binge eating disorder	The investigator's intellectual property will be used in the study. The technology is licensed by Spire Therapeutics, a privately traded company with which the investigator reports significant financial interest.	no			yes	Spire Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00205561	Tom Riis	Other	IRB_00175583	Noninvasive targeted neuromodulation for treatment of binge eating disorder	The investigator reports a significant financial interest with Spire Therapeutics, a non-publicly traded company providing a device for the study.	no			yes	Spire Therapeutics	Value cannot be readily determined	no	
CRV_00205575	Jan Kubanek	Principal Investigator	IRB_00162656	Ultrasonic brain stimulation for generalized chronic pain: A pilot study of target engagement and analgesic effects	The investigator reports that their licensed intellectual property licensed by Spire Therapeutics, a privately traded company for which the investigator is the founder and reports significant financial interest.	no			yes	Spire Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00205649	JAN PIERCE	Co-Investigator	IRB_00036454	Birth Tissues for Translational Research Studies	The investigator's licensed intellectual property may be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00205722	Jared Rutter	Principal Investigator	10069125	MECHANISMS OF METABOLITE SIGNALING	The investigator's intellectual property will be used in the project. The investigator reports significant financial interest in Atavistik Bio, the licensor of the technology.	yes	Atavistik Bio	\$40,000 to \$59,999	yes	Atavistik Bio	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00205744	Mary Beth Scholand	Principal Investigator	IRB_00170784	MINT: Nintedanib Plus Standard of Care Immunosuppression Versus Standard of Care Immunosuppression Alone in Patients with Progressive Fibrotic Myositis Associated - Interstitial Lung Disease: A Randomized, Double-Blind, Exploratory Trial	The investigator reports significant financial interest in the study sponsor Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00205746	Mary Beth Scholand	Co-Investigator	10069019	PHINDER: PULMONARY HYPERTENSION SCREENING IN PATIENTS WITH INTERSTITIAL LUNG DISEASE FOR EARLIER DETECTION	The investigator reports significant financial interest in United Therapeutics, the study sponsor.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00205747	Mary Beth Scholand	Principal Investigator	10070998	A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTINATIONAL, PHASE 3 STUDY OF THE EFFICACY AND SAFETY OF INHALED TREPROSTINIL IN SUBJECTS WITH PROGRESSIVE PULMONARY FIBROSIS	The investigator reports significant financial interest in UNITED THERAPEUTICS CORPORATION, the study sponsor.	yes	United Therapeutics	\$10,000 to \$19,999	no			no	
CRV_00205792	Christos Vakilavas	Co-Investigator	IRB_00173938	Pfizer C4891026 (SIRB) > Phase I/II Open Label, ARV-471 in Combination With PF-07220060 (CDK4 Inhibitor) For ER+, HER2-, Advanced Breast Cancer	The investigator reports significant financial interest in Pfizer, the study sponsor.	yes	Pfizer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00205819	Christos Vakilavas	Principal Investigator	IRB_00119281	AstraZeneca D8530C00001->>A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination in Women with ER-positive, HER2-negative Advanced Breast Cancer (SERENA-1)	The investigator reports significant financial interest in Pfizer, which manufactures one of the study medications (palbociclib). The investigator also reports significant financial interest in the study sponsor AstraZeneca.	yes	Pfizer Astrazeneca	\$5,000 to \$9,999 \$5,000 to \$9,999	no			no	
CRV_00206053	Kensaku Kawamoto	Other	10069657	AN AGE-FRIENDLY LEARNING HEALTHCARE SYSTEM: A TRANSFORMATIVE DIGITAL SOLUTION FOR GERIATRICS CLINICS	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00206403	Josef Stehlik	Other	IRB_00176863	A Comparative Effectiveness Study in Heart Transplant Patients of Rejection Surveillance with Cell-free DNA versus Endomyocardial Biopsy (ACES-EMB)	The investigator reports significant financial interest in the study sponsor, Natera.	yes	Natera	\$20,000 to \$39,999	no			no	
CRV_00206489	Tonya Di Sera	Other	IRB_00142987	ReSeq: Reanalysis of clinical rapid whole genomes	The investigator's intellectual property, licensed to Frameshift Labs, will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00206667	Shiven Patel	Principal Investigator	IRB_00177631	SWOG S1900G (NCI CIRB) >> Randomized Phase II Study of Capmatinib Plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)	The investigator reports significant financial interest with AstraZeneca, the manufacturer of Osimertinib.	yes	Astrazeneca	\$5,000 to \$9,999	no			no	
CRV_00206679	Shiven Patel	Co-Investigator	IRB_00097414	BMS CA209-816 >> Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816: CHECKpoint pathway and nivolumab clinical Trial	The Investigator reports significant financial interest with BMS, the sponsor of the project.	yes	BMS	\$5,000 to \$9,999	no			no	
CRV_00206687	Shiven Patel	Co-Investigator	IRB_00127115	STAGGER: A Randomized, Phase II Study of Staggered, Chemo-Immunotherapy with Durvalumab, MEDI4736 Pemetrexed and Carboplatin (PC) for Metastatic Non-Squamous NSCLC	The investigator reports significant financial interest with AstraZeneca, the study drug Durvalumab manufacturer.	yes	AstraZeneca	\$5,000 to \$9,999	no			no	
CRV_00206688	Shiven Patel	Co-Investigator	IRB_00145840	SWOG S1918 (CIRB) >> Phase II/III Randomized Study of R-MiniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and	The investigator reports significant financial interest from BMS, the study drug Azacitidine manufacturer.	yes	BMS	\$5,000 to \$9,999	no			no	
CRV_00206707	Shiven Patel	Co-Investigator	IRB_00143008	SWOG S1931 (NCI CIRB) >> Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)	The investigator reports significant financial interest with BMS, the study manufacturer of Nivolumab and Ipilimumab.	yes	BMS	\$5,000 to \$9,999	no			no	
CRV_00207326	Brook Martin	Other	IRB_00178477	Influence of an expanded mandatory bundled payment program on patient-reported outcomes, episode-of-care costs, procedure volume, and safety.	The investigator reports significant equity interest in Statix, LLC (formerly known as Gold Standard Research), a non-publicly traded company which was contracted for use of their web-enabled content management system to help collect patient-reported outcomes.	no			yes	STATIX, LLC	Value cannot be readily determined	no	
CRV_00207656	Mark Yandell	Principal Investigator	IRB_00178148	PCH Gene Kids: Primary Children's Hospital Genomic Initiative for Children	The investigator's intellectual property may be used in the study. The technology is licensed to Fabric Genomics and Backdrop Health, companies with which the investigator has a significant financial interest.	yes	Fabric Genomics Backdrop Health	\$80,000 to \$99,999 \$40,000 to \$59,999	yes	Fabric Genomics Backdrop Health	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00207708	Jan Kubanek	Co-Investigator	10072048	NONINVASIVE TARGETED TREATMENT OF ADDICTION: ULTRASONIC NEUROMODULATION OF DEEP NEURAL CIRCUITS	The investigator's intellectual property will be used in the project. The investigator a significant financial interest in Spire Therapeutics, the non-publicly traded company that licenses the intellectual property.	no			yes	Spire Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00207815	Marvin Moore	Other	IRB_00178148	PCH Gene Kids: Primary Children's Hospital Genomic Initiative for Children	The investigator's intellectual property will be used in the project. The investigator reports significant financial interest in Fabric Genomics, the licensor of the technology.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00207947	Travis Maak	Principal Investigator	10071676	BIOMECHANICAL STUDY ON FIXATION OPTIONS FOR LATERAL EXTRAARTICULAR TENODESIS PROCEDURE	The investigator reports significant financial interest in Arthrex, the project sponsor.	yes	Arthrex	Over \$100,000	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00208053	James Hotaling	Principal Investigator	IRB_00075836	Understanding the transcriptional and epigenetic dynamics in human spermatogonial stem cell self-renewal, proliferation, and differentiation	The investigator reports significant financial interest in Paterna Biosciences, a privately traded company which has licensed tangible property obtained through the project.	yes	Paterna Biosciences	\$20,000 to \$39,999	yes	Paterna Biosciences	Value cannot be readily determined	no	
CRV_00208054	Alexander Pastuszak	Co-Investigator	IRB_00075836	Understanding the transcriptional and epigenetic dynamics in human spermatogonial stem cell self-renewal, proliferation, and differentiation	The investigator reports significant financial interest in Paterna Biosciences, a privately traded company which has licensed tangible property obtained through the project.	no			yes	Paterna Biosciences	Value cannot be readily determined	no	
CRV_00208055	Kenneth Aston	Co-Investigator	IRB_00075836	Understanding the transcriptional and epigenetic dynamics in human spermatogonial stem cell self-renewal, proliferation, and differentiation	The investigator reports significant financial interest in Paterna Biosciences, a privately traded company which has licensed tangible property obtained through the project.	no			yes	Paterna Biosciences	Value cannot be readily determined	no	
CRV_00208093	Mary Beth Scholand	Principal Investigator	10070099	A2-COHORT, PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF VIXARELUMAB COMPARED WITH PLACEBO IN PATIENTS WITH IPF AND IN PATIENTS WITH SSC-ILD	The investigator reports significant financial interest in Genentech, the study sponsor.	yes	Genentech	\$5,000 to \$9,999	no			no	
CRV_00208230	Masood Parvania	Other	10052221	SOLARSTARTS: SOLAR-ASSISTED STATE-AWARE AND RESILIENT INFRASTRUCTURE SYSTEM	The investigator's intellectual property will be used in the project. Commercialization of the technology is imminent with Grid Modernization Solutions, LLC., a company in which the investigator has significant financial interest.	yes	Grid Modernization Solutions, L.L.C.	\$10,000 to \$19,999	yes	Grid Modernization Solutions, L.L.C.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00208245	Josef Stehlik	Co-Investigator	IRB_00178610	Sponsor-Initiated OCS Heart Perfusion (OHP-II) Registry	The investigator reports significant financial interest in TransMedics, the study sponsor.	no			yes	TransMedics	\$40,000 to \$59,999	no	
CRV_00208368	Josef Stehlik	Co-Investigator	10073252	SPONSOR-INITIATED OCS HEART PERFUSION (OHP-II) REGISTRY	The investigator reports significant financial interest in TransMedics, the study sponsor.	no			yes	TransMedics	Value cannot be readily determined	no	
CRV_00208373	Jan Kubanek	Co-Investigator	IRB_00179276	Ultrasonic brain stimulation for individuals using opioids for chronic pain	The investigator's intellectual property will be used in the project. The investigator a significant financial interest in Spire Therapeutics, the non-publicly traded company that licenses the intellectual property.	no			yes	Spire Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00208374	Tom Riis	Other	IRB_00179276	Ultrasonic brain stimulation for individuals using opioids for chronic pain	The investigator reports a significant financial interest in Spire Therapeutics, which will be involved in this project.	no			yes	Spire Therapeutics	Value cannot be readily determined	no	
CRV_00208658	Jan Kubanek	Co-Investigator	10068048	NONINVASIVE MODULATION OF DEEP BRAIN CIRCUITS FOR TREATMENT-RESISTANT DEPRESSION	The investigator's intellectual property will be used in the project. This technology is licensed to publicly traded Spire Therapeutics, a company in which the investigator reports significant financial interest.	no			yes	Spire Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00208677	Edward Dudek	Co-Investigator	10071073	BIOPAC, NIH SBIR: TEMPERATURE-CONTROLLED RECORDING SYSTEM FOR WIRELESS DATA ACQUISITION FROM IMMATURE RODENTS	The investigator's intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00208678	Andrew Zayachkivsky	Co-Investigator	10071073	BIOPAC, NIH SBIR: TEMPERATURE-CONTROLLED RECORDING SYSTEM FOR WIRELESS DATA ACQUISITION FROM IMMATURE RODENTS	The investigator's intellectual property will be studied in this project. This technology is licensed to BioPAC Systems Inc, a non-publicly traded company with which the investigator reports a significant financial interest.	yes	BioPAC	\$20,000 to \$39,999	no			yes	Value cannot be readily determined
CRV_00208722	Michael Free	Principal Investigator	10071348	ADVANCING CRITICAL MATERIALS SEPARATIONS TO PRODUCE HIGH PURITY RARE EARTH ELEMENTS USING SCIENCE-BASED, ENVIRONMENTALLY FRIENDLY, INNOVATIVE TECHNOLOGIES	This investigator's licensed intellectual properties will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00208752	Jared Rutter	Principal Investigator	10042808	Systematic Discovery of Protein-Metabolite Interactions: Technology Development and Implementation	The investigator reports significant financial interest in Atavistik Bio, collaborating with the study sponsor Calico Life Sciences to create products.	yes	Atavistik Bio	\$40,000 to \$59,999	yes	Atavistik Bio	Value cannot be readily determined	no	
CRV_00208844	Iqbal Ahmed	Principal Investigator	10070655	MASTER SERVICE AGREEMENT FOR PRE-CLINICAL RESEARCH PROJECTS	The investigator reports significant financial interest in the study sponsor, Elios Vision Inc.	yes	Elios Vision	Over \$100,000	yes	Elios Vision	Value cannot be readily determined	no	
CRV_00208974	Srinivas Tantravahi	Other	IRB_00159148	F. Hoffmann-La Roche CO43476 (sIRB) >> A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen Exposed Patients With Relapsed/Refractory Multiple Myeloma	The investigator reports significant financial interest in the study sponsor, Genentech Inc.	yes	Genentech	\$5,000 to \$9,999	no			no	
CRV_00209316	Mark Yandell	Principal Investigator	IRB_00096804	Genetics of Epilepsy Study	The investigator's intellectual property will be used in this project. The investigator reports significant financial interest in the companies that license the technology.	yes	Backdrop Health Inc Fabric Genomics	Zero to \$4,999 Over \$100,000	yes	Backdrop Health Inc Fabric Genomics	Value cannot be readily determined Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00209513	Edward Dudek	Principal Investigator	10058182	NIH/MGH R33: ANTICONVULSANT SCREENING USING CHRONIC EPILEPSY MODELS	The investigator's intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined
CRV_00209963	Mei Yee Koh	Principal Investigator	10070795	TARGETING IRON-SULFUR CLUSTER ASSEMBLY - A NOVEL VULNERABILITY IN KIDNEY CANCER	The investigator reports a significant financial interest with privately traded Kuda Therapeutics, who will be providing an investigational agent (KD061) used in this project.	yes	Kuda Therapeutics	\$10,000 to \$19,999	yes	Kuda Therapeutics	Value cannot be readily determined	no	
CRV_00210234	Shadrach Roundy	Principal Investigator	IRB_00176473	Evaluation of Self-powered Smart Insoles	The investigator reports a significant financial interest in Inviza Health, the study sponsor.	no			yes	INVIZA Health	Value cannot be readily determined	no	
CRV_00210335	Audra Hill	Other	10069977	AN AMBULATORY PELVIC FLOOR BIOFEEDBACK AND TRAINING DEVICE FOR USE IN PHYSICAL THERAPY	The investigator reports significant financial interest in the study sponsor, Freyya.	yes	Freyya	\$5,000 to \$9,999	no			no	
CRV_00210336	Audra Hill	Other	IRB_00168563	Ergonomic Assessment of an Ambulatory Pelvic Floor Biofeedback Device	The investigator reports significant financial interest in the study sponsor, Freyya.	yes	Freyya	\$5,000 to \$9,999	no			no	
CRV_00210550	Tonya Di Sera	Other	IRB_00125940	The Utah NeoSeq Project	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00211005	Allison Payne	Co-Investigator	10056825	NON-INVASIVE NONPHARMACEUTICAL TREATMENT FOR NECK PAIN: DEVELOPMENT OF CERVICAL SPINE-SPECIFIC MR-GUIDED FOCUSED ULTRASOUND SYSTEM.	The investigator's intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00211019	Allison Payne	Other	10071749	QUANTITATIVE MAGNETIC RESONANCE IMAGING FOR NON-INVASIVE BREAST CANCER THERAPY USING PHYSICS-INFORMED NEURAL NETWORKS.	The investigator's intellectual property will be involved in this project.	no			no			yes	Value cannot be readily determined
CRV_00211129	Matthew Rondina	Co-Investigator	IRB_00175150	The SENTRY Study: Testing Whether Changes in Platelet RNA Enhance the Early Diagnosis of Ovarian Cancer	The investigator's intellectual property will be used in the project. Commercialization of the technology is imminent through Code Genomics, a company in which the investigator reports a significant financial interest.	no			yes	Code Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00211281	Daniel Scoles	Principal Investigator	10074351	TARGETING STAU1 FOR TDP-43 PROTEINOPATHIES	The investigator's intellectual property will be used in the project. Commercialization of the technology is imminent.	no			no			yes	Value cannot be readily determined
CRV_00211321	Stefan Pulst	Principal Investigator	10074351	TARGETING STAU1 FOR TDP-43 PROTEINOPATHIES	The investigator's intellectual property will be used in the project. Commercialization of the technology is imminent.	no			no			yes	Value cannot be readily determined
CRV_00211332	RANDALL PETERSON	Principal Investigator	10069431	MULTIMODAL PHENOTYPING OF ZEBRAFISH MODELS OF HUMAN DISEASE	The investigator's licensed intellectual property will be used in the project.	no			no			yes	Value cannot be readily determined
CRV_00211368	Jan Kubanek	Principal Investigator	IRB_00173042	Deep Brain Therapy with Low-intensity Ultrasound for Treatment of Cognitive Impairment	The investigator's licensed intellectual property will be used in the project. The investigator reports a significant financial interest in the licensor Spire Therapeutics.	no			yes	Spire Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00211513	Gerald Gleich	Co-Investigator	IRB_00173311	Prediction of Labor by Measurement of Eosinophil Granule Major Basic Protein	The investigator reports significant financial interest in NexEos Diagnostics, the project sponsor.	yes	NexEos Diagnostics, Inc.	Over \$100,000	yes	NexEos Diagnostics, Inc.	Value cannot be readily determined	no	
CRV_00211538	Iqbal Ahmed	Principal Investigator	10072223	OPTIMIZING OUTFLOW FACILITY WITH VALASE FEMTOSECOND LASER TRABECULOTOMY	The investigator reports significant financial interest in the sponsor, Valase Inc.	yes	Valase Inc.	\$80,000 to \$99,999	yes	Valase Inc.	Value cannot be readily determined	no	
CRV_00211570	Shadrach Roundy	Principal Investigator	10070351	SELF-CHARGING, MEDICAL-GRADE WEARABLE SMART INSOLE TECHNOLOGY FOR REAL-TIME NON-INVASIVE BIO-SENSING, PHYSICAL STATE MONITORING, HEALTH PROTECTION, AND SAFETY MONITORING USING EDGE AND CLOUD COMPUTING	The investigator reports significant financial interest in Inviza Health, the study sponsor.	no			yes	INVIZA Health	Value cannot be readily determined	no	
CRV_00211596	Mary Beth Scholand	Principal Investigator	IRB_00177650	1305-0031 (FIBRONEER-ON): An open-label extension trial of the long-term safety and efficacy of B1 1015550 taken orally in patients with idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF)	The investigator reports significant financial interest in the study sponsor Boehringer Ingelheim.	yes			no			no	
CRV_00212390	Ramesh Grandhi	Principal Investigator	IRB_00155821	THE SQUID TRIAL FOR THE EMBOLIZATION OF THE MIDDLE MENINGEAL ARTERY (STEM) FOR TREATMENT OF CHRONIC SUBDURAL HEMATOMA (CIP-201912-SQUID)	The investigator reports significant financial interest in Balt Neurovascular, the sponsor of the project.	yes	Balt Neurovascular	\$5,000 to \$9,999	no			no	
CRV_00212458	Ramesh Grandhi	Principal Investigator	10063056	BALT: THE SQUID TRIAL FOR THE EMBOLIZATION OF THE MIDDLE MENINGEAL ARTERY FOR TREATMENT OF CHRONIC SUBDURAL HEMATOMA (STEM)	The investigator reports significant financial interest Balt Neurovascular, the sponsor of the project.	yes	Balt Neurovascular	\$5,000 to \$9,999	no			no	
CRV_00212588	JUSTIN ENGLISH	Principal Investigator	10074641	DIRECTED EVOLUTION OF CELL-TYPE SPECIFIC ON-DEMAND SIGNALING CONTROL SYSTEMS	The investigator's intellectual property will be used in this project. The investigator reports significant financial interest in Evolution Bio, which holds the license to the intellectual property and is involved in this project.	no			yes	Evolution Bio	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00212627	MARK CLEMENT	Co-Investigator	10070228	COMPUTATIONAL TOOLS FOR PRECISION GENOME EDITING	The investigator reports significant financial interest in Edilytics, Inc. The investigator also reports that their non-university intellectual property will be used in this project. This property is licensed to Edilytics, Inc.	yes	Edilytics, Inc.	Over \$100,000	yes	Edilytics, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00212628	Tom Riis	Other	IRB_00173062	Low-Intensity Ultrasonic Brain Stimulation for Treatment of Post-Traumatic Stress Disorder	The investigator reports significant financial interest in Spire Therapeutics, the company that produces the device used in this trial.	no			yes	Spire Therapeutics	Value cannot be readily determined	no	
CRV_00212629	Tom Riis	Other	IRB_00173042	Deep Brain Therapy with Low-Intensity Ultrasound for Treatment of Cognitive Impairment	The investigator reports significant financial interest in Spire Therapeutics, the company that produces the device used in this trial.	no			yes	Spire Therapeutics	Value cannot be readily determined	no	
CRV_00212630	Jan Kubanek	Principal Investigator	IRB_00175546	Noninvasive modulation of chronic neuropathic pain with focused ultrasonic waves	The investigator's intellectual property will be used in the project. The investigator reports significant financial interest in Spire Therapeutics, the licensor of the technology.	no			yes	Spire Therapeutics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00212724	Jonathan Tward	Co-Investigator	10070210	THE ABILITY OF THE PROLARIS BIOPSY CLINICAL CELL-CYCLE RISK (CCR) SCORE TO PREDICT LYMPH NODE STATUS AT RADICAL PROSTATECTOMY	The investigator reports significant financial interest in Myriad Genetics, the study sponsor.	yes	MYRIAD GENETICS INC	\$5,000 to \$9,999	no			no	
CRV_00213021	Robert Tashjian	Principal Investigator	10071685	TORNIER PERFORM HUMERAL SYSTEM FRACTURE STUDY (PFx).	The investigator reports significant financial interest in Stryker Orthopedics, the sponsor of this project.	yes	Stryker	Over \$100,000	no			no	
CRV_00213023	Robert Tashjian	Principal Investigator	10064163	TORNIER PERFORM STEMLESS REVERSE IDE STUDY	The investigator reports significant financial interest in Stryker, the study sponsor and manufacturer of the prosthesis being compared.	yes	Stryker	Over \$100,000	no			no	
CRV_00213027	Robert Tashjian	Principal Investigator	10060122	PERFORM HUMERAL SYSTEM STUDY (PHS)	The investigator reports a significant financial interest in Stryker Orthopedics, the sponsor of this project.	yes	Stryker	Over \$100,000	no			no	
CRV_00213031	Robert Tashjian	Principal Investigator	IRB_00158645	PERFORM Humeral System Study (PHS)	The investigator reports a significant financial interest in Stryker Orthopedics, the sponsor of this project.	yes	Stryker Orthopedics	Over \$100,000	no			no	
CRV_00213037	Robert Tashjian	Principal Investigator	IRB_00167669	Finite element modelling of glenoid bone-implant interfaces	The investigator reports a significant financial interest in Stryker Orthopedics, the sponsor of this project.	yes	Stryker Orthopedics	Over \$100,000	no			no	
CRV_00213052	Robert Tashjian	Principal Investigator	IRB_00153484	TORNIER PERFORM™ Stemless Reverse IDE	The investigator reports significant financial interest in Stryker, the study sponsor and manufacturer of the prosthesis being compared.	yes	Stryker	Over \$100,000	no			no	
CRV_00213056	Paul Bernstein	Principal Investigator	IRB_00116610	Lutein & Zeaxanthin in Pregnancy (L-ZIP) - Carotenoid Supplementation During Pregnancy: Ocular and Systemic Effects	The investigator reports significant financial interest in Kemin Health, the manufacturer of the investigational product.	yes	Kemin Health	\$5,000 to \$9,999	no			no	
CRV_00213136	Jacob George	Principal Investigator	IRB_00124231	Can an array of micro-electrodes implanted in a human nerve record neural signals and provide sensory feedback useful for controlling a prosthetic device? (HAPTIX FDA IDE Approval)	The investigator's intellectual property will be used in the study. The technology is licensed to the study sponsor BIOS, a non-publicly traded company with which the investigator holds a significant financial interest.	yes	BIOS	\$20,000 to \$39,999	yes	BIOS	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00213563	Florian Solzbacher	Principal Investigator	10059295	ADVANCING EPILEPSY DIAGNOSIS WITH FLEXIBLE, HIGH-RESOLUTION THIN-FILM ELECTRODES	The investigator reports significant financial interest in Blackrock Microsystems, a non-publicly traded company building the electrodes for the study.	yes	Blackrock Microsystems	Over \$100,000	yes	Blackrock Microsystems	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00214034	Jacob George	Principal Investigator	10063790	OPTIMAL FEATURE GENERATION FOR PERIPHERAL NERVE INTERFACES TO GUIDE THE DEVELOPMENT OF DEXTEROUS NEUROPROSTHESES	The investigator's intellectual property will be used in the study. The technology is licensed to the study sponsor BIOS, a non-publicly traded company with which the investigator holds a significant financial interest in equity interest and remuneration.	yes	BIOS	\$20,000 to \$39,999	yes	BIOS	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00214328	Jeremy Gilliland	Co-Investigator	IRB_00173261	Retrieval and Examination of the Prosthetic Device Being Removed During Revision of a Total Joint	The investigator's financial interests may be related to the broad aims of this research.	yes	Stryker	Over \$100,000	no			no	
CRV_00214329	Christopher Pelt	Co-Investigator	IRB_00173261	Retrieval and Examination of the Prosthetic Device Being Removed During Revision of a Total Joint	The investigator's financial interests may be related to the broad aims of this research.	yes	Total Joint Orthopaedics Smith and Nephew	\$60,000 to \$79,999 \$20,000 to \$39,999	no			no	
CRV_00214390	Richard Lemons	Other	IRB_00169881	CSL222_3003: An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B	The investigator reports significant financial interest in CSL Behring, the manufacturer of the study medication.	yes	CSL Behring	\$40,000 to \$59,999	no			no	
CRV_00214888	Lubdha Shah	Co-Investigator	10056825	NON-INVASIVE NONPHARMACEUTICAL TREATMENT FOR NECK PAIN: DEVELOPMENT OF CERVICAL SPINE-SPECIFIC MR-GUIDED FOCUSED ULTRASOUND SYSTEM.	The investigator's intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00215067	Mary Steinbach	Other	IRB_00105512	Juno Therapeutics 017004>>>An Open-Label, Phase 1/2 Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)	The investigator reports significant financial interest in Bristol Meyer Squibb, which is the parent company to the study sponsor, Juno Therapeutics.	yes	Bristol Meyer Squibb	\$5,000 to \$9,999	no			no	
CRV_00215073	Mary Steinbach	Other	IRB_00116779	Celgene BB2121-MM-003>>>A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Regimens in Subjects with Relapsed and Refractory Multiple Myeloma (KarMMa-3)	The investigator reports significant financial interest in Bristol Meyer Squibb, (parent company to the study sponsor Celgene). The investigator reports significant financial interest with Janssen, manufacturer of study drug daratumumab.	yes	Bristol Meyer Squibb Janssen	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00215077	Mary Steinbach	Other	IRB_00130881	Janssen JNJ-68284528MMY3002 >> A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and Dexamethasone (Pvd) or Daratumumab, Pomalidomide and Dexametha	The investigator reports significant financial interest in Janssen, the study sponsor. The investigator reports significant financial interest in BMS, parent company of pomalidomide manufacturer Celgene.	yes	Janssen BMS	\$10,000 to \$19,999 \$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00215079	Mary Steinbach	Other	IRB_00147063	Pfizer C1071009 (SIRB) >> A Phase 1/2, Open-Label, Multicenter Study to Evaluate a Dosing Regimen with Two Step-Up Priming Doses and Longer Dosing Intervals of Etranatamab (PF-06863135) Monotherapy in Participants with Relapsed/Refractory Multiple Myelom	The investigator reports significant financial interest in Pfizer, the study sponsor.	yes	Pfizer	\$5,000 to \$9,999	no			no	
CRV_00215083	Mary Steinbach	Other	IRB_00123033	Janssen 54767414MMY3021>>A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Ce	The investigator reports significant financial interest in Janssen, the study sponsor. The investigator reports significant financial interest in BMS, parent company of lenalidomide manufacturer Celgene.	yes	Janssen Bristol Myers Squibb	\$10,000 to \$19,999 \$5,000 to \$9,999	no			no	
CRV_00215085	Mary Steinbach	Other	IRB_00094455	Alliance A061402 (CIRB)>>Solitary Plasmacytoma of Bone: Randomized Phase III Trial To Evaluate Treatment With Adjuvant Systemic Treatment And Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy	The investigator reports significant financial interest in Bristol Meyer Squibb, (parent company to one of the study drug manufacturers, Celgene).	yes	Bristol Meyer Squibb	\$5,000 to \$9,999	no			no	
CRV_00215088	Mary Steinbach	Other	IRB_00125677	Celgene CC-220-MM-001>> A Phase 1b/2a Multicenter, Open-Label, Dose Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Cc-220 Monotherapy and in Combination with Other Treatments I	The investigator reports significant financial interest in Bristol Meyer Squibb, (parent company to the study sponsor Celgene). The investigator reports significant financial interest in Janssen, manufacturer of study drug daratumumab.	yes	Janssen Bristol Meyer Squibb	\$10,000 to \$19,999 \$5,000 to \$9,999	no			no	
CRV_00215089	Mary Steinbach	Other	IRB_00122217	Celgene GC-LTFU-001 >> Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells.	The investigator reports significant financial interest in Bristol Meyer Squibb, (parent company to the study sponsor Celgene).	yes	Bristol Meyer Squibb	\$5,000 to \$9,999	no			no	
CRV_00215090	Mary Steinbach	Other	IRB_00158591	AbbVie M22-947 (SIRB) >> A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company to lenalidomide manufacturer Celgene. The investigator reports significant financial interest in Janssen, manufacturer of study drug daratumumab.	yes	Janssen Bristol Meyer Squibb	\$10,000 to \$19,999 \$5,000 to \$9,999	no			no	
CRV_00215091	Mary Steinbach	Other	IRB_00166032	University of Illinois at Chicago HEME-18 >> Post-Autologous Transplant Maintenance with Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company to lenalidomide manufacturer Celgene.	yes	Bristol Meyer Squibb	\$5,000 to \$9,999	no			no	
CRV_00215092	Mary Steinbach	Other	IRB_00148976	Janssen 64007957MMY3001 (SIRB) >> A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DvD) in Partic	The investigator reports significant financial interest in Janssen, the study sponsor. The investigator reports significant financial interest in BMS, parent company of pomalidomide manufacturer Celgene.	yes	Bristol Myers Squibb JANSSEN PHARMACEUTICAL INC	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00215093	Mary Steinbach	Other	IRB_00174406	Janssen 68284528MMY2003 (sIRB) >> A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA in Subjects with Multiple Myeloma (CARTITUDE-2)	The investigator reports significant financial interest in Janssen, which is the study sponsor. The investigator reports significant financial interest in BMS, parent company of lenalidomide manufacturer Celgene.	yes	Bristol Myers Squibb JANSSEN PHARMACEUTICAL INC	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00215094	Mary Steinbach	Other	IRB_00139305	ECOG-ACRIN EAA181 (CIRB): Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase III Trial for Newly Diagnosed Multiple Myeloma Not Intended For Early Autologous Transplantation	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company to lenalidomide manufacturer Celgene. The investigator reports significant financial interest in Janssen, manufacturer of study drug daratumumab.	yes	Bristol Meyer Squibb Janssen	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00215095	Mary Steinbach	Other	IRB_00128092	ECOG-ACRIN EAA173 (NCI CIRB)>>Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)	The investigator reports significant financial interest in Bristol Meyer Squibb, (parent company to Revlimid manufacturer Celgene) and Janssen (manufacturer of Daratumumab).	yes	Janssen Bristol Meyer Squibb	\$10,000 to \$19,999 \$5,000 to \$9,999	no			no	
CRV_00215097	Mary Steinbach	Other	IRB_00162354	Janssen 64407564MMY3002 >> A Phase 3 Randomized Study Comparing Talquetamab SC in Combination With Daratumumab SC and Pomalidomide (Tal-DP) or Talquetamab SC in Combination With Daratumumab SC (Tal-D) Versus Daratumumab SC, Pomalidomide and Dexamethasone	The investigator reports significant financial interest in Janssen, the study sponsor. The investigator reports significant financial interest in BMS, parent company of Pomalidomide manufacturer Celgene.	yes	Bristol Myers Squibb JANSSEN PHARMACEUTICAL INC	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00215098	Mary Steinbach	Other	IRB_00143188	Celgene BB2121-EAP-001 >> Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel that is Nonconforming for Commercial Release	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company to the study sponsor Celgene.	yes	Bristol Meyer Squibb	\$5,000 to \$9,999	no			no	
CRV_00215099	Mary Steinbach	Other	IRB_00152032	BeiGene BGB-11417-105 >> A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company to pomalidomide manufacturer Celgene. The investigator reports significant financial interest in Janssen, manufacturer of study drug daratumumab.	yes	Bristol Meyer Squibb Janssen	\$5,000 to \$9,999 \$10,000 to \$19,999	no			no	
CRV_00215101	Mary Steinbach	Other	IRB_00130745	SWOG S1803 (CIRB) >> Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Du	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company of the lenolidomide manufacturer Celgene. The investigator reports significant financial interest in Janssen, manufacturer of Daratumumab.	yes	Janssen Bristol Meyer Squibb	\$10,000 to \$19,999 \$5,000 to \$9,999	no			no	
CRV_00215103	Mary Steinbach	Other	IRB_00144612	University of Miami ADVANCE >> Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone in Patients with Newly-Diagnosed Multiple Myeloma (ADVANCE)	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company lenalidomide manufacturer Celgene. The investigator reports significant financial interest in Janssen, manufacturer of study drug daratumumab.	yes	Janssen Bristol Meyer Squibb	\$10,000 to \$19,999 \$5,000 to \$9,999	no			no	
CRV_00215104	Mary Steinbach	Other	IRB_00138747	ETCTN 10076 (CIRB)>>A Phase 1 Dose-Escalation And Exploratory Dose Expansion Study Of KRT-232 (AMG 232) In Combination with Carfilzomib, Lenalidomide, And Dexamethasone In Relapsed And/Or Refractory Myeloma	The investigator reports significant financial interest in Bristol Meyer Squibb, parent company to lenalidomide manufacturer Celgene.	yes	Bristol Meyer Squibb	\$5,000 to \$9,999	no			no	
CRV_00215106	Mary Steinbach	Other	IRB_00102833	Janssen 54767414AMY3001>>A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared with CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis.	The investigator reports significant financial interest in Janssen, the study sponsor.	yes	Janssen	\$10,000 to \$19,999	no			no	
CRV_00215175	Barbara Wirosko	Co-Investigator	IRB_00183002	Usability and Demographic Data from a Large-Scale iCare HOME2 Patient Cohort	The investigator reports significant financial interest in the privately traded company MyEyes LLC, which distributes the iCare HOME2 tonometer.	no			yes	MyEyes LLC	\$40,000 to \$59,999	no	
CRV_00215925	Mark Yandell	Other	10070957	EMPOWERING INTEROPERABLE GENOMICS-ENABLED LEARNING HEALTH SYSTEMS AT SCALE	The investigator reports significant financial interest in Backdrop Health Inc, and Fabric Genomics, both of which are involved in this project.	yes	Fabric Genomics	Over \$100,000	yes	Fabric Genomics Backdrop Health Inc.	Value cannot be readily determined Value cannot be readily determined	no	
CRV_00216197	JAMIE DWYER	Co-Investigator	IRB_00176056	A Phase III, Randomized, Double -Blind, Active-controlled Study to Assess the Efficacy, Safety and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on Chronic Kidney Disease (CKD) Progression in Participant	This investigator reports significant financial interest in the study sponsor, AstraZeneca.	yes	AstraZeneca Pharmaceuticals	\$20,000 to \$39,999	no			no	
CRV_00216505	Tommaso Lenzi	Principal Investigator	10052194	LIGHTWEIGHT POWERED PROSTHESIS FOR ABOVE-KNEE AMPUTEES	The investigator's licensed intellectual property is being used in the study.	no			no			yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00216526	Mary Beth Scholand	Principal Investigator	10072368	AN OPEN-LABEL EXTENSION TRIAL OF THE LONG-TERM SAFETY AND EFFICACY OF BI 1015550 TAKEN ORALLY IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF) AND PROGRESSIVE PULMONARY FIBROSIS (PPF) (FIBRONEER-ON)	The investigator reports significant financial interest in the study sponsor Boehringer Ingelheim.	yes	Boehringer Ingelheim	\$10,000 to \$19,999	no			no	
CRV_00216600	Stavros Drakos	Principal Investigator	IRB_00182128	Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients with Advancing Heart Failure (TEAM-HF)	The investigator reports a significant financial interest in Abbott, the sponsor of the project.	yes	Abbott	\$5,000 to \$9,999	no			no	
CRV_00216679	Stavros Drakos	Principal Investigator	IRB_00143654	Prospective, Randomized-Controlled, Non-blinded, Multi-center trial to compare standard-of-care LVAD unloading plus HF medications reverse-remodeling management versus hemodynamics-guided LVAD unloading with the use of the wireless monitoring system Card	The investigator reports significant financial interest with Abbott, the sponsor of the project.	yes	Abbott	\$5,000 to \$9,999	no			no	
CRV_00216685	Stavros Drakos	Principal Investigator	IRB_00177262	Home-based Exercise Program Using Mobile Technology After LVAD Implantation: MOVE-LVAD II Study	The Investigator reports significant financial interest in Abbott Laboratories, the manufacturer of the HM3 LVAD.	yes	Abbott	\$5,000 to \$9,999	no			no	
CRV_00217058	Robert Gray	Principal Investigator	10042036	Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the SAPIEN 3 Interventional THV	The investigator reports significant financial interest with Edwards Lifesciences, the project sponsor.	yes	Edwards Lifescience	\$5,000 to \$9,999	no			no	
CRV_00217059	Robert Gray	Principal Investigator	10066361	MULTICENTER POST-APPROVAL STUDY OF CONGENITAL PULMONIC VALVE DYSFUNCTION STUDYING THE EDWARDS SAPIEN 3 TRANSCATHETER PULMONARY VALVE SYSTEM WITH ALTERRA ADAPTIVE PRESTENT	The investigator reports significant financial interest with Edwards Lifesciences, the study sponsor.	yes	Edwards Lifesciences	\$5,000 to \$9,999	no			no	
CRV_00217067	Robert Gray	Principal Investigator	IRB_00091551	COMPASSION S3 Congenital Multicenter trial of Pulmonic Valve Dysfunction Studying the Sapien 3 Interventional THV	The investigator reports significant financial interest with Edwards Lifesciences, the study sponsor.	yes	Edwards Lifescience	\$5,000 to \$9,999	no			no	
CRV_00217070	Robert Gray	Principal Investigator	IRB_00156951	Multicenter Post-Approval Study of Congenital Pulmonic Valve Dysfunction Studying the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent (ALTERRA Post-Approval Study)	The investigator reports significant financial interest with Edwards Lifesciences, the study sponsor.	yes	Edwards Lifesciences	\$5,000 to \$9,999	no			no	
CRV_00217072	Robert Gray	Principal Investigator	IRB_00141051	Congenital Multicenter Trial of Pulmonic Valve Dysfunction Studying the Sapien 3 Interventional THV Post-Approval Study (COMPASSION PAS)	The investigator reports significant financial interest in Edwards Lifesciences, the project sponsor.	yes	Edwards Lifesciences	\$5,000 to \$9,999	no			no	
CRV_00217412	Ramesh Grandhi	Other	IRB_00183731	Clinical Investigation Plan of the Artisse™ Intrascacular Device IDE (Artisse IDE)	The Investigator has a significant financial interest in Medtronic, the parent organization of study sponsor MICRO THERAPEUTICS INC.	yes	Medtronic	\$5,000 to \$9,999	no			no	
CRV_00217521	Ariel Richer	Principal Investigator	10072631	ASSESSING ATTITUDES AND BELIEFS ABOUT PSYCHEDELICS AND INDIGENOUS PLANT MEDICINES AMONG AN URBAN INDIGENOUS COMMUNITY	The investigator reports significant financial interest in Urban Indigenous Collective, which is involved in this project.	yes	Urban Indigenous Collective	\$40,000 to \$59,999	no			no	
CRV_00217522	Ariel Richer	Principal Investigator	IRB_00180065	Assessing Attitudes and Beliefs about Psychedelics and Indigenous Plant Medicines Among an Urban Indigenous Community	The investigator reports significant financial interest in Urban Indigenous Collective, which is involved in this project.	yes	Urban Indigenous Collective	\$40,000 to \$59,999	no			no	
CRV_00218093	Jason Glotzbach	Principal Investigator	10071336	THORAFLEX HYBRID AND RELAY EXTENSION POST-APPROVAL STUDY	The investigator reports significant financial interest with the study sponsor Terumo Aortic.	yes	Terumo Aortic	\$5,000 to \$9,999	no			no	
CRV_00218118	Jason Glotzbach	Co-Investigator	IRB_00172726	Thoraflex Hybrid and Relay Extension Post-Approval Study (EXTEND)	The investigator reports significant financial interest in Terumo Aortic, the study sponsor.	yes	Terumo Aortic	\$5,000 to \$9,999	no			no	
CRV_00218153	Josef Stehlik	Principal Investigator	10063860	INTERHEART DD-CFDNA-HLA CALIBRATION STUDY	The investigator reports a significant financial interest in Natera Inc., the manufacturer of the Prospera test being used in the study.	yes	Natera	\$20,000 to \$39,999	no			no	
CRV_00218159	Rock Hadley	Co-Investigator	10056825	NON-INVASIVE NONPHARMACEUTICAL TREATMENT FOR NECK PAIN: DEVELOPMENT OF CERVICAL SPINE-SPECIFIC MR-GUIDED FOCUSED ULTRASOUND SYSTEM.	The investigator's intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00218160	Viola Rieke	Principal Investigator	10056825	NON-INVASIVE NONPHARMACEUTICAL TREATMENT FOR NECK PAIN: DEVELOPMENT OF CERVICAL SPINE-SPECIFIC MR-GUIDED FOCUSED ULTRASOUND SYSTEM.	The investigator's intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00218187	Joshua Schiffman	Co-Investigator	IRB_00125940	The Utah NeoSeq Project	The investigator reports significant financial interest in Fabric Genomics, that creates tools that will be used in the analysis.	no			yes	Fabric Genomics	Value cannot be readily determined	no	
CRV_00218216	Ramesh Grandhi	Principal Investigator	10074138	MICRO THERAPEUTICS: ARTISSE INTRASCACULAR DEVICE IDE	The Investigator has significant financial interest in Medtronic, the parent organization of MICRO THERAPEUTICS INC, the sponsor of this project.	yes	Medtronic	\$5,000 to \$9,999	no			no	
CRV_00218751	Michael YU	Principal Investigator	10071033	LOCALIZATION OF ANTIBODY DRUGS TO ARTHRITIC JOINTS VIA COLLAGEN HYBRIDIZATION	The investigator's intellectual property will be used in this project. They also report significant financial interest in 3Helix, Inc., which is involved in the project and licenses the intellectual property.	no			yes	3Helix, Inc.	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00218944	Stavros Drakos	Co-Investigator	10073780	INVESTIGATION OF A NOVEL, MAGNETICALLY LEVITATED VAD FOR THE TREATMENT OF REFRACTORY LEFT VENTRICULAR HEART FAILURE (INNOVATE TRIAL)	The investigator reports significant financial interest in Abbott, the manufacturer of the HeartMate 3.	yes	Abbott	\$5,000 to \$9,999	no			no	
CRV_00219041	Luke Maese	Other	IRB_00022067	AALL0434: Intensified Methotrexate, Nelarabine (Compound 506U78; IND#52611) and Augmented BFM Therapy for Children and Young Adults with Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL)	The investigator reports significant financial interest with Jazz Pharmaceuticals, which manufactures the study drug CRISANTASPACE.	yes	Jazz Pharmaceuticals	\$10,000 to \$19,999	no			no	
CRV_00219283	Richard Lemons	Principal Investigator	10070344	AN EXTENSION STUDY ASSESSING THE LONG-TERM SAFETY AND EFFICACY OF ETRANACOGENE DEZAPARVOVEC (CSL222) PREVIOUSLY ADMINISTERED TO ADULT MALE SUBJECTS WITH HEMOPHILIA B	The investigator reports significant financial interest in CSL Behring, the manufacturer of the study medication.	yes	CSL Behring	\$40,000 to \$59,999	no			no	
CRV_00219338	Jeffrey Rosenbluth	Co-Investigator	IRB_00184982	Survey-Driven Development of Assistive Devices for SCI Patients	The investigator's licensed intellectual property will be involved in this project.	no			no			yes	Value cannot be readily determined
CRV_00219940	Stavros Drakos	Co-Investigator	IRB_00179839	Investigation of a Novel, magnetically levitated VAD for the treatment of refractory left Ventricular heart failure (INNOVATE Trial)	The investigator reports significant financial interest in Abbott, the manufacturer of the HeartMate 3.	yes	Abbott	\$5,000 to \$9,999	no			no	
CRV_00220145	Diana Brixner	Other	IRB_00171401	The Clinical and Economic Benefit of Immediate Postpartum Insertion of Intrauterine Device: A Retrospective Study	The investigator reports significant financial interest from Bayer, the study sponsor.	yes	Bayer	\$10,000 to \$19,999	no			no	
CRV_00220322	Robert Tashjian	Principal Investigator	IRB_00180529	Functional and radiographic outcomes after patient matched implant utilized during reverse total shoulder arthroplasty	The investigator reports significant financial interest with Stryker, which will be involved in this project.	yes	Stryker	Over \$100,000	no			no	
CRV_00220488	Claude Nanjo	Other	IRB_00183730	Sociotechnical Design and Evaluation of Disease Manager Modules	The investigator's intellectual property will be involved in this project.	no			no			yes	Value cannot be readily determined
CRV_00220680	Audra Hill	Co-Investigator	10075748	SBIR PHASE I: AN AMBULATORY PELVIC FLOOR MONITORING AND FEEDBACK DEVICE FOR USE IN PHYSICAL THERAPY	The investigator reports significant financial interest with Freyya, the sponsor of the project.	yes	Freyya	\$5,000 to \$9,999	no			no	
CRV_00221639	Jacob George	Principal Investigator	10075326	BIOS TASK ORDER 3	The investigator reports significant financial interest with BIOS, the project sponsor. The investigator's intellectual property will be used in this project.	yes	BIOS	\$10,000 to \$19,999	yes	BIOS	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00222073	Mary Steinbach	Co-Investigator	IRB_00181496	Janssen 64407564MMY3009 (sIRB) >> A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexameth	The investigator reports significant financial interest with study drug manufacturer Bristol Meyer Squibb and with the study sponsor Janssen.	yes	Bristol Meyer Squibb Janssen Pharmaceuticals	\$5,000 to \$9,999 \$20,000 to \$39,999	no			no	
CRV_00222378	Scott Uhrlich	Principal Investigator	IRB_00186623	Evaluation of human movement and wearable devices	The investigator reports significant financial interest with Model Health Inc., a non-publicly traded company which has licensed an extended version of open-source software related to the study.	yes	Model Health Inc.	\$5,000 to \$9,999	yes	Model Health Inc.	Value cannot be readily determined	no	
CRV_00222432	Srinivas Tantravahi	Principal Investigator	10070276	PHASE I/II, OPEN-LABEL, DOSE-ESCALATION, SAFETY, PHARMACOKINETIC, AND PHARMACODYNAMIC STUDY OF ORAL TP-3654 IN PATIENTS WITH INTERMEDIATE OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS	The investigator reports a significant financial interest with GLAXOSMITHKLINE, manufacturer of study drug momelotinib.	yes	GLAXOSMITHKLINE	\$5,000 to \$9,999	no			no	
CRV_00222437	Srinivas Tantravahi	Principal Investigator	10066690	TREATMENT FREE REMISSION AFTER COMBINATION THERAPY WITH ASCIMINIB (ABL001) PLUS IMATINIB IN CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CP-CML) PATIENTS WHO RELAPSED AFTER A PRIOR ATTEMPT AT TKI DISCONTINUATION.	The investigator reports a significant financial interest with Novartis, study sponsor and manufacturer of study drugs Asciminib and Imatinib.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222442	Srinivas Tantravahi	Principal Investigator	10068910	PHASE II MULTICENTER, OPEN-LABEL, SINGLE-ARM DOSE ESCALATION STUDY OF ASCIMINIB MONOTHERAPY IN 2ND LINE CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA (ASC2ESCALATE)	The investigator reports significant financial interest with the study sponsor, Novartis.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222448	Srinivas Tantravahi	Principal Investigator	10068634	ASCIMINIB AS INITIAL THERAPY FOR PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE	The investigator reports significant financial interest with the study sponsor, Novartis.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222451	Srinivas Tantravahi	Co-Investigator	IRB_00128202	Novartis CMBG453C12201 >> A Phase II multi-center, single arm, safety and efficacy study of MBG453 in combination with azacitidine and venetoclax for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit for chemotherapy	The investigator reports a significant financial interest with Novartis, the study sponsor.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222459	Srinivas Tantravahi	Principal Investigator	IRB_00118462	SWOG S1712 (NCI CIRB) >>A Randomized Phase II Study of Ruxolitinib in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Patients with Evidence of Molecular Disease	The investigator reports significant interest with Novartis, the manufacturer of the study drug Nilotinib.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222478	Srinivas Tantravahi	Co-Investigator	IRB_00164578	MCW/CML Consortium HJKC3-0004 (SIRB) >> Asciminib as Initial Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase	The investigator reports a significant financial interest with Novartis, manufacturer of study drug Asciminib.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222489	Srinivas Tantravahi	Co-Investigator	IRB_00158717	Medical College of Wisconsin/CML Consortium HJKC3-0003 (SIRB) >> Treatment Free Remission After Combination Therapy with Asciminib (ABL001) Plus Imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TK	The investigator reports a significant financial interest with study sponsor Novartis.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222492	Srinivas Tantravahi	Principal Investigator	IRB_00165327	Novartis CABL001AUS08 (sIRB) >> A Phase II multicenter, open-label, single-arm dose escalation study of Asciminib monotherapy in 2nd Line Chronic Phase – Chronic Myelogenous Leukemia (ASC2ESCALATE)	The investigator reports significant financial interest with the study sponsor, Novartis.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222497	Srinivas Tantravahi	Principal Investigator	IRB_00180093	Novartis CMBG453B12206B >> An Open-Label, Multicenter, Roll-Over Study for Patients who have Completed a Prior Novartis-Sponsored Sabatolimab (MBG453) Study and are Judged by the Investigator to Benefit from Continued Treatment with Sabatolimab	The investigator reports significant financial interest in Novartis, the study sponsor.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222499	Srinivas Tantravahi	Principal Investigator	IRB_00105165	Novartis CABL001A2301>>A Phase 3, Multi-Center, Open-Label, Randomized Study Of Oral Asciminib Versus Bosutinib in Patients With Chronic Myelogenous Leukemia In Chronic Phase (CML-CP), Previously Treated With 2 Or More Tyrosine Kinase Inhibitors	The investigator reports a significant financial interest with Novartis, the study sponsor.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00222718	Jared Rutter	Other	10072746	TARGETING MCT4 INHIBITS MYELOFIBROSIS	The investigator reports significant financial interest in Vettore, a non-publicly traded company which is providing a molecule for the project.	yes	Vettore	\$10,000 to \$19,999	yes	Vettore	Value cannot be readily determined	no	
CRV_00222838	ALUSTAIR WARD	Other	IRB_00178148	PCH Gene Kids: Primary Children's Hospital Genomic Initiative for Children	The investigator reports significant financial interest with Frameshift Labs, Inc, which will be involved in this project.	yes	Frameshift Labs, Inc	Over \$100,000	yes	Frameshift Labs, Inc	Value cannot be readily determined	no	
CRV_00222881	HANNAH IMLAY	Co-Investigator	IRB_00182313	A Phase 2 Clinical Study of REC-3964 in Adults for the Reduction of Recurrent Clostridioides Difficile Infection	The investigator reports significant financial interest in Recursion Pharmaceuticals, the study sponsor.	no			yes	Recursion Pharmaceuticals	\$20,000 to \$39,999	no	
CRV_00223186	Daniel Ermann	Co-Investigator	IRB_00184585	A Phase 2 study of Loncastuximab tesirine and Rituximab as Bridging Therapy prior to Standard-of-care CD19 CAR T-cell therapy in patients with large B-cell lymphoma	The investigator reports significant financial interest in ADC Therapeutics, a manufacturer of one of the study drugs, Loncastuximab.	yes	ADC Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00223206	Daniel Ermann	Co-Investigator	IRB_00181535	Lonca-R after SRS in CNSL: A Phase 1 Study of Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery (SRS) in Patients with Primary and Secondary Central Nervous System Lymphomas	The investigator reports a significant financial interest with ADC Therapeutics, the study sponsor.	yes	ADC Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00223209	Daniel Ermann	Co-Investigator	IRB_00179982	ADC Therapeutics ADCT-402-105 (sIRB) >> A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma	The investigator reports significant financial interest with ADC Therapeutics, the study sponsor.	yes	ADC Therapeutics	\$5,000 to \$9,999	no			no	
CRV_00223238	Julia Batten	Co-Investigator	IRB_00108683	SWOG S1609 (CIRB)>>DART: DUAL ANTI-CTLA-4 AND ANTI-PD-1 BLOCKADE IN RARE TUMORS	The investigator reports significant financial interest with Bristol-Myers Squibb, the manufacturer of study drugs ipilimumab and nivolumab.	yes	BRISTOL-MYERS SQUIBB	\$5,000 to \$9,999	no			no	
CRV_00223577	Stavros Drakos	Co-Investigator	10074420	TRIAL TO EVALUATE SAFETY AND EFFECTIVENESS OF MECHANICAL CIRCULATORY SUPPORT IN PATIENTS WITH ADVANCING HEART FAILURE	The investigator reports a significant financial interest in Abbott, the sponsor of the project.	yes	Abbott	\$5,000 to \$9,999	no			no	
CRV_00223613	Mary Beth Scholand	Principal Investigator	IRB_00184324	AP01-007 (MIST): A Randomized, Double-Blind, Placebo-Controlled, Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)	The investigator reports significant financial interest with the study sponsor, Avalyn Pharma Inc.	yes	AVALYN PHARMA INC	\$5,000 to \$9,999	no			no	
CRV_00223711	Michael Free	Principal Investigator	10071702	NEXT GENERATION DISRUPTIVE CRITICAL MATERIALS SEPARATION AND PURIFICATION TECHNOLOGIES BASED ON NEW MATERIALS AND METHODS	The investigator's licensed intellectual property will be used in this project.	no			no			yes	Value cannot be readily determined
CRV_00223762	PEI SUN	Co-Investigator	10071702	NEXT GENERATION DISRUPTIVE CRITICAL MATERIALS SEPARATION AND PURIFICATION TECHNOLOGIES BASED ON NEW MATERIALS AND METHODS	The investigator's intellectual property will be used in the study. The technology is licensed to Blacksand Technology, a non-publicly traded company in which the investigator reports a significant financial interest. The investigator also reports significant financial interest with Iperion X Technology, a non-publicly traded company which has acquired Blacksand.	yes	IPERIONX TECHNOLOGY LLC BLACKSAND TECHNOLOGY LLC	\$80,000 to \$99,999 \$20,000 to \$39,999	yes	IPERIONX TECHNOLOGY LLC	Value cannot be readily determined	yes	Value cannot be readily determined

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)					Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest								
ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00224693	Gabor Marth	Co-Investigator	IRB_00115011	University of Utah - Intermountain West Clinical Site for the Undiagnosed Disease Network (UDN)	The investigator's intellectual property may be utilized in this project. The technology is licensed to Frameshift Labs, Inc, a non-publicly traded company in which the investigator reports a significant financial interest.	no			yes	Frameshift Labs Inc	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00224753	ALISTAIR WARD	Co-Investigator	10065476	7/7 CTSA RC2 PROGRAM AT UNIVERSITY OF UTAH: A TRANSLATIONAL PLATFORM FOR RAPID GENOMIC MEDICINE	The investigator's intellectual property is being used in the project. The technology is licensed to Frameshift Labs, a non-publicly traded company in which the investigator reports significant financial interest.	yes	Frameshift Labs	Over \$100,000	yes	Frameshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00224758	ALISTAIR WARD	Other	IRB_00167500	siRB: Congenital Heart Disease Genetic Network (CHD Genes)	The investigator's intellectual property will be used in this project. The technology is licensed to Frameshift Labs, a non-publicly traded company with which the investigator reports a significant financial interest.	yes	Framshift Labs	Over \$100,000	yes	Framshift Labs	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00224881	LAWRENCE CARR	Other	IRB_00182200	A Pilot Study Evaluating the Efficacy of Targeted Photobiomodulation in Individuals with Concussion and/or Mild to Moderate TBI.	The investigator reports significant financial interest with Vielight Inc, the manufacturer of Vielight Neuro RX Duo photobiomodulation device.	yes	Vielight, Inc	\$20,000 to \$39,999	no			no	
CRV_00227244	Srinivas Tantravahi	Co-Investigator	10073948	OPEN-LABEL, MULTICENTER, ROLL-OVER STUDY FOR PATIENTS WHO HAVE COMPLETED A PRIOR NOVARTIS-SPONSORED SABATOLIMAB (MBG453) STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH SABATOLIMAB	The investigator reports significant financial interest in Novartis, the study sponsor.	yes	Novartis	\$5,000 to \$9,999	no			no	
CRV_00227679	Jason Glotzbach	Co-Investigator	IRB_00158353	Terumo Aortic Global Endovascular Registry (TIGER-001)	The investigator reports a significant financial interest with Terumo Aortic, parent company of the study sponsor Bolton Medical.	yes	Terumo Aortic	\$5,000 to \$9,999	no			no	
CRV_00229096	PEI SUN	Co-Investigator	10071088	ADVANCED PROCESSING FOR CRITICAL MATERIALS EXTRACTION, RECOVERY, SEPARATION, AND PURIFICATION	The investigator's intellectual property will be used in the study. The technology is licensed to Blacksand Technology, a non-publicly traded company in which the investigator reports a significant financial interest. The investigator also reports significant financial interest with Iperion X Technology, a non-publicly traded company which has acquired Blacksand.	yes	BLACKSAND TECHNOLOGY LLC IPERIONX TECHNOLOGY LLC	\$20,000 to \$39,999 \$80,000 to \$99,999	yes	IPERIONX TECHNOLOGY LLC	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00229143	Zhigang Fang	Co-Investigator	10071088	ADVANCED PROCESSING FOR CRITICAL MATERIALS EXTRACTION, RECOVERY, SEPARATION, AND PURIFICATION	The investigator's intellectual property will be used in the study. The technology is licensed to Blacksand Tech, a non-publicly traded company in which the investigator reports a significant financial interest. The investigator also reports a significant financial interest in Iperionx Technology LLC, the parent company of Blacksand Technology.	no			yes	IPERIONX TECHNOLOGY LLC Blacksand Technology LLC	Over \$100,000 Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00229148	Zhigang Fang	Co-Investigator	10071702	NEXT GENERATION DISRUPTIVE CRITICAL MATERIALS SEPARATION AND PURIFICATION TECHNOLOGIES BASED ON NEW MATERIALS AND METHODS	The investigator's intellectual property will be used in the study. The technology is licensed to Blacksand Tech, a non-publicly traded company in which the investigator reports a significant financial interest. The investigator also reports a significant financial interest in Iperionx Technology LLC, the parent company of Blacksand Technology.	no			yes	IPERIONX TECHNOLOGY LLC Blacksand Technology LLC	Over \$100,000 Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00229460	Marvin Moore	Other	10072422	COMORBID DISEASE IN WOMEN WITH PRIMARY OVARIAN INSUFFICIENCY	The investigator's intellectual property will be used in the project. The technology is licensed to Fabric Genomics, a non-publicly traded company in which the investigator reports a significant financial interest.	yes	Fabric Genomics	\$20,000 to \$39,999	yes	Fabric Genomics	Value cannot be readily determined	yes	Value cannot be readily determined
CRV_00229829	Srinivas Tantravahi	Principal Investigator	IRB_00169214	Sumitomo Pharma BBI-TP-3654-102 >> A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis	The investigator reports a significant financial interest with GLAXOSMITHKLINE, manufacturer of study drug momelotinib.	yes	GLAXOSMITHKLINE	\$5,000 to \$9,999	no			no	
CRV_00230219	Ramesh Grandhi	Co-Investigator	IRB_00150322	A Prospective, Randomized, Controlled, Interventional Clinical Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical MonoPoint® Reperfusion System for Aspiration Embolectomy in Acute Ischemic Stroke Patients (SUMMIT)	The investigator reports a significant financial interest with Stryker, manufacturer of the AXS Vecta Aspiration System.	yes	Stryker	\$5,000 to \$9,999	no			no	
CRV_00230273	Ramesh Grandhi	Principal Investigator	IRB_00171961	Evaluate Endovascular Treatment of Acutely Ruptured Shallow Intradural Aneurysms with the Pipeline™ Flex Embolization Device with Shield Technology™ (ELEVATE)	The investigator reports significant financial interest in Medtronic, the study sponsor.	yes	Medtronic	\$5,000 to \$9,999	no			no	
CRV_00230556	Ramesh Grandhi	Co-Investigator	IRB_00136326	Embolization of the Middle Meningeal Artery with ONYX™ Liquid Embolic System in the Treatment of Subacute and Chronic Subdural Hematoma (EMBOLISE)	The investigator reports significant financial interest in Medtronic, the study sponsor and manufacturer of the ONYX™ Liquid Embolic System utilized in this study.	yes	Medtronic	\$5,000 to \$9,999	no			no	
CRV_00230692	Ramesh Grandhi	Co-Investigator	10070160	MEDTRONIC: (ELEVATE) EVALUATE ENDOVASCULAR TREATMENT OF ACUTELY RUPTURED SHALLOW INTRADURAL ANEURYSMS WITH THE PIPELINE FLEX EMBOLIZATION DEVICE WITH SHIELD TECHNOLOGY STUDY	The investigator reports significant financial interest in Medtronic, the study sponsor.	yes	Medtronic	\$5,000 to \$9,999	no			no	
CRV_00230853	Ramesh Grandhi	Co-Investigator	10055732	MEDTRONIC: EMBOLIZATION OF THE MIDDLE MENINGEAL ARTERY WITH ONYXTM LIQUID EMBOLIC SYSTEM IN THE TREATMENT OF SUBACUTE AND CHRONIC SUBDURAL HEMATOMA (EMBOLISE)	The investigator reports significant financial interest in Medtronic, the study sponsor and manufacturer of the ONYX™ Liquid Embolic System utilized in this study.	yes	Medtronic	\$5,000 to \$9,999	no			no	
CRV_00231229	Mary Steinbach	Other	IRB_00188466	BMS CA0881007 (WCG) >> A Phase III, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of BMS-986393, a GPRC5D-directed CAR-T Cell Therapy, Versus Standard Regimens in Adult Participants with Relapsed or Refractory and Lenalidom	The investigator reports significant financial interest with study drug manufacturers, Janssen and with the study sponsor Bristol Meyer Squibb.	yes	Bristol Meyer Squibb Janssen	\$5,000 to \$9,999 \$20,000 to \$39,999	no			no	
CRV_00231363	Kristen Kelley	Other	IRB_00109587	ETCTN 10020 (CIRB)>> A Phase II Open-Label, Randomized Study of PARP Inhibition (olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-	The investigator reports significant financial interest with Abbvie, the manufacturer of the study drug, veliparib (ABT-888).	yes	Abbvie	\$10,000 to \$19,999	no			no	
CRV_00232245	Julia Batten	Co-Investigator	IRB_00179672	ETCTN 10301 (NCI CIRB) >>A Phase I and Randomized Phase II Trial of Radium-223 dichloride, M3814, & Avelumab in Advanced Metastatic Castrate-Resistant Prostate Cancer (mCRPC)	The investigator reports significant financial interest in EMD Serono, the manufacturer of the study drug, Avelumab.	yes	EMD Serono	\$10,000 to \$19,000	no			no	
CRV_00232268	Julia Batten	Co-Investigator	IRB_00143008	SWOG S1931 (NCI CIRB) >> Phase III Trial of Immunotherapy-Based Combination Therapy With or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (Probe Trial)	The investigator reports significant remuneration from EMD Serono, the manufacturer of Avelumab, a study drug. The investigator reports a significant remuneration with Bristol Myers Squibb, manufacturer of Nivolumab and Ipilimumab. The investigator also reports a significant remuneration with Pfizer Pharmaceuticals, manufacturer of Axitinib.	yes	EMD Serono Pfizer Bristol-Myers Squibb	\$10,000 to \$19,000 \$5,000 to \$9,999 \$5,000 to \$9,999	no			no	
CRV_00232271	Mary Steinbach	Other	IRB_00188732	Alliance A062101 (CIRB) >> A Phase I/II Study of the Safety, Tolerability, and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refracto	The investigator reports significant financial interest in Bristol Meyer Squibb, the manufacturer of Iberdomide, the investigational agent.	yes	Bristol Meyer Squibb	\$5,000 to \$9,999	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's Identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00232895	Jonathan Finnoff	Co-Investigator	IRB_00189086	Development and Validation of an Adapted SCAT6 Tool for Use Among Athletes Who Use Wheelchairs	The investigator reports significant financial interest with the United States Olympic and Paralympic Committee (USOPC), which will maintain the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	Over \$100,000	no			no	
CRV_00232896	Travis Anderson	Co-Investigator	IRB_00189086	Development and Validation of an Adapted SCAT6 Tool for Use Among Athletes Who Use Wheelchairs	The investigator reports significant financial interest with the United States Olympic and Paralympic Committee (USOPC), which will maintain the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	\$80,000 to \$99,999	no			no	
CRV_00232897	Ashley Triplett	Co-Investigator	IRB_00189086	Development and Validation of an Adapted SCAT6 Tool for Use Among Athletes Who Use Wheelchairs	The investigator reports significant financial interest with the United States Olympic and Paralympic Committee (USOPC), which will maintain the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	\$60,000 to \$79,999	no			no	
CRV_00232898	Eric Post	Principal Investigator	IRB_00189086	Development and Validation of an Adapted SCAT6 Tool for Use Among Athletes Who Use Wheelchairs	The investigator reports significant financial interest with the United States Olympic and Paralympic Committee (USOPC), which will maintain the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	\$80,000 to \$99,999	no			no	
CRV_00232999	Daniel Ermann	Co-Investigator	IRB_00087788	Acerta ACE-LY-003>>An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects with B-cell Non-Hodgkin Lymphoma	The investigator reports a significant financial interest with AstraZeneca, the parent company to the study sponsor Acerta Pharma.	yes	AstraZeneca, parent company of Acerta Pharma	\$5,000 to \$9,999	no			no	
CRV_00233360	Scott Uhlich	Principal Investigator	10074902	NOVEL DIGITAL MOVEMENT BIOMARKERS FOR MYOTONIC DYSTROPHY USING SMARTPHONE VIDEO	The investigator reports significant financial interest and equity with Model Health Inc., a non-publicly traded company which has licensed an extended version of open-source software related to the study.	yes	Model Health Inc.	\$5,000 to \$9,999	yes	Model Health Inc.	Value cannot be readily determined	no	
CRV_00233798	Julia Batten	Other	IRB_00084004	NRG/ECOG/ACRIN/NCI EAY131 >> (CIRB) Molecular Analysis for Therapy Choice (MATCH)	The investigator reports a significant financial interest in Bristol-Myers Squibb (the manufacturer of study drug Nivolumab), and in Bayer Pharmaceuticals (the manufacturer of study drug LOXO-101/Copanlisib).	yes	Bayer Pharmaceuticals Bristol-Myers Squibb	\$5,000 to \$9,999 \$5,000 to \$9,999	no			no	
CRV_00233799	Julia Batten	Other	IRB_00113845	Gilead Sciences, Inc. IMMU-132-06>>A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer	The investigator reports a significant financial interest with EMD Serono, the manufacturer of the study drug avelumab.	yes	EMD Serono	\$10,000 to \$19,999	no			no	
CRV_00233801	Julia Batten	Co-Investigator	IRB_00172154	ImmuneSensor IMSA101-102 (SIRB) >> Phase 2 Randomized Clinical Trial Comparing the Safety and Efficacy of PULSAR-Integrated Radiotherapy + Pembrolizumab or Nivolumab Administered with or without STING-Agonist IMSA101 in Patients with Oligometastatic Non-	The investigator reports a significant financial interest in Bristol-Myers Squibb, the manufacturer of Nivolumab.	yes	Bristol-Myers Squibb	\$5,000 to \$9,999	no			no	
CRV_00233803	Julia Batten	Co-Investigator	IRB_00155838	ECTIN 10483 (NCI CIRB) >> Phase IB Trial of Erdafitinib Combined with Enfortumab Vedotin Following Platinum and PD1/L1 Inhibitors For Metastatic Urothelial Carcinoma with FGFR2/3 Genetic Alterations	The investigator reports a significant financial interest with Seagen Inc (the co-manufacturer of the study drug Enfortumab vedotin), a subsidiary of Pfizer.	yes	Seagen Inc (subsidiary of Pfizer)	\$10,000 to \$19,999	no			no	
CRV_00233805	Julia Batten	Co-Investigator	IRB_00126006	Rad2Nivo: A Phase IB Study of Nivolumab in Combination with Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer	The investigator reports a significant financial interest in Bristol-Myers Squibb, the manufacturer of Nivolumab.	yes	Bristol-Myers Squibb	\$5,000 to \$9,999	no			no	
CRV_00233816	Julia Batten	Co-Investigator	IRB_00176158	AstraZeneca D9723C00001 (SIRB) >> A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate	The investigator reports a significant financial interest in Bayer Pharmaceuticals, the manufacturer of study drug Darolutamide.	yes	Bayer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00233821	Julia Batten	Co-Investigator	IRB_00105905	Pfizer C3441021>>APHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER	The investigator reports significant financial interest with Seagen Inc. (formerly Seattle Genetics), a subsidiary of Pfizer, the sponsor of the study.	yes	Seagen Inc (formerly Seattle Genetics) subsidiary of Pfizer	\$5,000 to \$9,999	no			no	
CRV_00233833	Julia Batten	Co-Investigator	IRB_00142990	Pfizer C3441052 (SIRB) >> TALAPRO-3: A Phase 3, Randomized, Double-Blind, Study of Talazoparib with Enzalutamide Versus Placebo with Enzalutamide in Men with DDR Gene Mutated Metastatic Castration-Sensitive Prostate Cancer	The investigator reports significant financial interest with Seagen Inc. (formerly Seattle Genetics), a subsidiary of Pfizer, the sponsor of the study.	yes	Seagen Inc. (formerly Seattle Genetics) subsidiary of Pfizer	\$5,000 to \$9,999	no			no	
CRV_00233837	Julia Batten	Co-Investigator	IRB_00172719	Seagen RC48G001 (SIRB) >> A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Meta	The investigator reports significant financial interest with Seagen Inc. (formerly known as Seattle Genetics), the sponsor of the study.	yes	Seagen	\$5,000 to \$9,999	no			no	
CRV_00233853	Julia Batten	Co-Investigator	IRB_00158922	NRG GU010 (NCI CIRB) >> Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (GUIDANCE)	The investigator reports significant financial interest with Bayer Pharmaceuticals, the manufacturer of study drug Darolutamide.	yes	Bayer Pharmaceuticals	\$5,000 to \$9,999	no			no	
CRV_00233855	Julia Batten	Co-Investigator	IRB_00182315	Pfizer C2321014 (SIRB) >> A Phase 3, Randomized, Open-Label Study of PF-06821497 (Mevrometostat) in Combination with Enzalutamide Compared with Enzalutamide or Docetaxel in Participants with Metastatic Castration Resistant Prostate Cancer Previously Trea	The investigator reports significant financial interest with Seagen Inc. (formerly known as Seattle Genetics), a subsidiary of Pfizer, the sponsor of the study.	yes	Seagen Inc. (formerly known as Seattle Genetics), a subsidiary of Pfizer	\$5,000 to \$9,999	no			no	
CRV_00234051	Jonathan Finnoff	Co-Investigator	IRB_00189558	Development of a New Psychological Services Documentation Form for the USOPC	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	Over \$100,000	no			no	
CRV_00234052	Travis Anderson	Co-Investigator	IRB_00189558	Development of a New Psychological Services Documentation Form for the USOPC	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	\$80,000 to \$99,999	no			no	
CRV_00234053	Ashley Triplett	Co-Investigator	IRB_00189558	Development of a New Psychological Services Documentation Form for the USOPC	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	nited States Olympic and Paralympic Committee (USOPC)	\$60,000 to \$79,999	no			no	
CRV_00234054	Eric Post	Co-Investigator	IRB_00189558	Development of a New Psychological Services Documentation Form for the USOPC	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	\$80,000 to \$99,999	no			no	
CRV_00234055	Jonathan Finnoff	Co-Investigator	IRB_00189552	Developing a Novel Triage Tool for the Sport Mental Health Assessment Tool (SMHAT)	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	Over \$100,000	no			no	
CRV_00234056	Travis Anderson	Co-Investigator	IRB_00189552	Developing a Novel Triage Tool for the Sport Mental Health Assessment Tool (SMHAT)	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC),	\$80,000 to \$99,999	no			no	
CRV_00234057	Ashley Triplett	Co-Investigator	IRB_00189552	Developing a Novel Triage Tool for the Sport Mental Health Assessment Tool (SMHAT)	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	\$60,000 to \$79,999	no			no	
CRV_00234058	Eric Post	Principal Investigator	IRB_00189552	Developing a Novel Triage Tool for the Sport Mental Health Assessment Tool (SMHAT)	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which collected and maintains the data for the study.	yes	United States Olympic and Paralympic Committee (USOPC)	\$80,000 to \$99,999	no			no	

Individual Conflict of Interest Public Disclosures as of April 15, 2025 (if required for public disclosure)

Updated within 60 calendar days of the University's identification of a new Financial Conflict of Interest

ID	Discloser	Title and Role	Linked ID	Linked Title	Description of Conflict	Remuneration	Remuneration Name	Remuneration Amount	Equity	Equity Name	Equity Value	Intellectual Property	Intellectual Property Value
CRV_00234648	Jonathan Finnoff	Co-Investigator	IRB_00189602	Investigating the Efficacy of Brief Behavioral Therapy for Insomnia in Elite Athletes	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which oversees the US national teams which will be enrolled in the research.	yes	United States Olympic and Paralympic Committee (USOPC)	Over \$100,000	no			no	
CRV_00234649	Travis Anderson	Co-Investigator	IRB_00189602	Investigating the Efficacy of Brief Behavioral Therapy for Insomnia in Elite Athletes	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which oversees the US national teams which will be enrolled in the research.	yes	United States Olympic and Paralympic Committee (USOPC)	\$80,000 to \$99,999	no			no	
CRV_00234650	Ashley Triplett	Co-Investigator	IRB_00189602	Investigating the Efficacy of Brief Behavioral Therapy for Insomnia in Elite Athletes	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which oversees the US national teams which will be enrolled in the research.	yes	United States Olympic and Paralympic Committee (USOPC)	\$60,000 to \$79,999	no			no	
CRV_00234651	Eric Post	Principal Investigator	IRB_00189602	Investigating the Efficacy of Brief Behavioral Therapy for Insomnia in Elite Athletes	The investigator reports significant financial interest with United States Olympic and Paralympic Committee (USOPC), which oversees the US national teams which will be enrolled in the research.	yes	United States Olympic and Paralympic Committee (USOPC)	\$80,000 to \$99,999	no			no	
CRV_00234974	Daniel Ermann	Co-Investigator	IRB_00141431	CORONADO CLL: Phase Ib/II Trial of Combination Camonsertib (RP-3500) and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia	The investigator reports significant financial interest in AstraZeneca, the manufacturer of study drug olaparib.	yes	AstraZeneca	\$5,000 to \$9,999	no			no	